Inhibitors and degraders of PIP4k protein
Compounds targeting PIP4K2A, PIP4K2B, and PIP4K2C activity or levels address dysregulation in the PI5P4K pathway, offering therapeutic benefits for diseases and immune enhancement.
Patent Information
- Application Number
- US19/482426
- Authority / Receiving Office
- US · United States
- Patent Type
- Applications(United States)
- Current Assignee / Owner
- Priority Date
- 2024-04-05
- Filing Date
- 2024-05-09
- Publication Date
- 2026-11-12
AI Technical Summary
Dysregulation of the PI5P4K signaling pathway is linked to diseases such as diabetes, neurodegenerative disorders, and cancers, and existing methods do not effectively target the catalytic activity of PIP4K isoforms for therapeutic intervention.
Development of compounds that inhibit or degrade PIP4K kinase activity, specifically targeting PIP4K2A, PIP4K2B, and PIP4K2C, to modulate their activity or levels, thereby treating associated diseases.
The compounds effectively reduce PIP4K activity or levels, providing therapeutic potential for treating various diseases and enhancing immune function.
Smart Images

Figure US20260355196A1-D00000_ABST
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 63 / 465,458, filed May 10, 2023; U.S. Provisional Application No. 63 / 611,367, filed Dec. 18, 2023; and U.S. Provisional Application No. 63 / 575,561, filed Apr. 5, 2024; the contents of which are hereby incorporated by reference in their entirety for all purposes.BACKGROUND
[0002] The phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks), consisting of the three isoforms, PI5P4Kα, β, and γ, are lipid kinases that catalyze phosphorylation of phosphatidylinositol 5-phosphate (PI5P) on its 4-position to form phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) (Rameh et al., Nature 390(6656):192-196 (1997). In the cellular membrane, PI-4,5-P2 is also produced by another signaling pathway in which phosphatidylinositol 4-phosphate (PI4P) is phosphorylated by phosphatidylinositol 4-phosphate 5-kinases (PI4P5Ks).
[0003] Although the majority of PI-4,5-P2 is produced via the PI4P5K pathway, PI5P4Ks have been recognized as key regulators of many cell functions including metabolism, stress response, autophagy, and immunological processes (Hu et al., J. Lipid Res. 59:507-514 (2018); Lamia et al., Mol. Cell. Biol. 24(11):5080-5087 (2004); Shim et al., Proc. Natl. Acad. Sci. U.S.A 113(27):7596-7601 (2016); Al-Ramahi et al., eLife 6:e29123 (2017); Lundquist et al., Mol. Cell 70(3):531-543 (2018); Bulley et al., Proc. Natl. Acad. Sci. U.S.A 113(38):10571-10576 (2016); Keune et al., Adv. Biol. Regul. 53(2):179-189 (2013)). PIP4Ks have distinct catalytic and non-catalytic functions in controlling cellular metabolism and suppress PIP5K activity and insulin-stimulated production of PI(3,4,5)P3 (Wang et al., Cell Rep. 27:1991-2001 (2019)).
[0004] Dysregulation of the PI5P4K signaling pathway has been further linked to diseases such as diabetes, neurodegenerative disorders, and cancers (Lamia et al., Mol. Cell. Biol. 24(11): 5080-5087 (2004); Al-Ramahi et al., eLife 6:e29123 (2017); Jude et al., Oncogene 34(10):1253-1262 (2015); Luoh et al., Oncogene 23:1354-1363 (2004); Emerling et al., Cell 155(4):844-857 (2013). Analysis of PI(4,5)P2 levels in cells with single or double knockdown of PIP4K isoforms revealed an additive effect among all three isoforms that does not correlate with their relative catalytic activities. Double knockdown of the most active isoforms, PIP4KA / B, failed to phenocopy the triple knockdown, suggesting that catalytic activity is not the most important factor in regulating PI(4,5)P2 levels (Wang et al., Cell Rep. 27:1991-2001 (2019), and suggesting a unique role for PIP4KC.
[0005] These findings indicate that the inhibition of PI5P4K kinase activity and / or degradation of PI4P4K might have therapeutic potential across various diseases.SUMMARY OF THE INVENTION
[0006] In one aspect, provided is a compound of Formula (I′):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q, V, R, Ring 1, Ring 3, and Ring 4 are as detailed herein.In one aspect, provided is a compound of Formula (I):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q, V, R, Ring 1, Ring 3, and Ring 4 are as detailed herein. In some variations, the embodiments provided herein also apply to a compound of Formula (I′), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.In some embodiments of the compound of Formula (I), Q is Ring 5, which is as detailed herein. In some embodiments, provided is a compound of Formula (II):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein V, R, Ring 1, Ring 3, Ring 4, and Ring 5 are as detailed herein. In some variations, the embodiments provided herein also apply to a compound of Formula (I′), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.In some embodiments of the compound of Formula (I), Q is RQ, which is as detailed herein. In some embodiments, provided is a compound of Formula (III):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein V, R, Ring 1, Ring 3, Ring 4, and RQ are as detailed herein. In some variations, the embodiments provided herein also apply to a compound of Formula (I′), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.In some embodiments of the compound of Formula (I), Q is of Formula (i)wherein Ring A, X, Ring B, W, Ring C, Linker, U, and Ring 2 are as detailed herein. In some embodiments, provided is a compound of Formula (IV):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Ring A, X, Ring B, W, Ring C, Linker, U, Ring 2, V, Ring 1, Ring 3, and Ring 4 are as detailed herein. In some variations, the embodiments provided herein also apply to a compound of Formula (I′), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.In another aspect, provided is a pharmaceutical composition comprising a compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, provided is a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In another aspect, provided is a pharmaceutical composition comprising a compound of Formula (I′), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, provided is a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I′), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier.In another aspect, provided is a method of making a compound of Formula (I), (II), (III), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In another aspect, provided is a method of making a compound of Formula (I′), or any related formula such as Formula (I), (II), (III), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.In another aspect, provided is a method of treating a disease or disorder comprising modulating (e.g., reducing) the activity or level of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering (a) a compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, the method comprises reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the level of PIP4K2C. In some embodiments, the method comprises selectively degrading PIP4K2C. In another aspect, provided is a method of treating a disease or disorder comprising modulating (e.g., reducing) the activity or level of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering (a) a compound of Formula (I′), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I′), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, the method comprises reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the level of PIP4K2C. In some embodiments, the method comprises selectively degrading PIP4K2C.In another aspect, provided is a method of treating a disease or disorder comprising modulating (e.g., reducing) the activity or level of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering (a) a therapeutically effective amount of the compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, the method comprises reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the level of PIP4K2C. In some embodiments, the method comprises selectively degrading PIP4K2C. In some embodiments, the methods are selective for PIP4K2C over PIP4K2A. In some embodiments, the methods are selective for PIP4K2C over PIP4K2B. In some embodiments, the methods are selective for PIP4K2C over both PIP4K2A and PIP4K2B. In another aspect, provided is a method of treating a disease or disorder comprising modulating (e.g., reducing) the activity or level of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering (a) a therapeutically effective amount of the compound of Formula (I′), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula (I′), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, the method comprises reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the activity of PIP4K2C. In some embodiments, the method comprises selectively reducing the level of PIP4K2C. In some embodiments, the method comprises selectively degrading PIP4K2C. In some embodiments, the methods are selective for PIP4K2C over PIP4K2A. In some embodiments, the methods are selective for PIP4K2C over PIP4K2B. In some embodiments, the methods are selective for PIP4K2C over both PIP4K2A and PIP4K2B.In another aspect, provided is a method of treating a disease or disorder comprising modulating (e.g., reducing) the level of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering (a) a compound of Formula (IV), or any related formula such as (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (IV), or any related formula such as (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to a subject in need thereof. In some embodiments, the method comprises reducing the level of PIP4K2C. In some embodiments, the method comprises selectively reducing the level of PIP4K2C. In some embodiments, the method comprises degrading PIP4K2C. In some embodiments, the method comprises selectively degrading PIP4K2C.In another aspect, provided is a method of treating a disease or disorder comprising modulating (e.g., reducing) the level of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering (a) a therapeutically effective amount of the compound of Formula (IV), or any related formula such as (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (IV), or any related formula such as (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier, to a subject in need thereof. In some embodiments, the method comprises reducing the level of PIP4K2C. In some embodiments, the method comprises degrading PIP4K2C. In some embodiments, the method comprises selectively reducing the level of PIP4K2C. In some embodiments, the method comprises selectively degrading PIP4K2C.In another aspect, provided is a method of enhancing immune function in a subject in need thereof, comprising administering to a subject (a) a compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In another aspect, provided is a method of enhancing immune function in a subject in need thereof, comprising administering to a subject (a) a compound of Formula (I′), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I′), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier.
[0018] In some embodiments, provided is a method of enhancing immune function in a subject in need thereof, comprising administering to a subject (a) a therapeutically effective amount of the compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or pharmaceutically acceptable salt of any of the foregoing, or a (b) pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, provided is a method of enhancing immune function in a subject in need thereof, comprising administering to a subject (a) a therapeutically effective amount of the compound of Formula (I′), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or pharmaceutically acceptable salt of any of the foregoing, or a (b) pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula (I′), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier.
[0019] In some aspects, the present invention is directed to methods of stimulating the immune system comprising reducing scaffolding or interaction of at least one of PIP4K2A, PIP4K2B, and PIP4K2C with at least one of PIP4K2A, PIP4K2B, or phosphatidylinositol-4-phosphate 5-kinase (PIP5K) in a subject in need thereof, comprising administering to a subject (a) a compound of Formula (I), (II), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I), (II), (III), (III), or (IV), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, the method comprises reducing the scaffolding or interaction of PIP4K2C with at least one of PIP4K2A, PIP4K2B, or phosphatidylinositol-4-phosphate 5-kinase (PIP5K). In some aspects, the present invention is directed to methods of stimulating the immune system comprising reducing scaffolding or interaction of at least one of PIP4K2A, PIP4K2B, and PIP4K2C with at least one of PIP4K2A, PIP4K2B, or phosphatidylinositol-4-phosphate 5-kinase (PIP5K) in a subject in need thereof, comprising administering to a subject (a) a compound of Formula (I′), or any related formula such as Formula (I), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or pharmaceutically acceptable salt of any of the foregoing, or (b) a pharmaceutical composition comprising a compound of Formula (I′), or any related formula such as Formula (I), (II), (III), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier. In some embodiments, the method comprises reducing the scaffolding or interaction of PIP4K2C with at least one of PIP4K2A, PIP4K2B, or phosphatidylinositol-4-phosphate 5-kinase (PIP5K).
[0020] Any embodiments provided herein of a compound of formula (I) or (I′), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof, apply where applicable to any other formula detailed herein, the same as if each and every embodiment were specifically and individually listed. Thus, it is understood and described that each embodiment provided herein of a compound of formula (I) or (I′), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof, such as embodiments related to Ring 1, Ring 2, Ring 3, Ring 4, Ring 5, Ring A, Ring B, Ring C, R, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, RC, RD, RL, RQ, RV, Rw, Rx, Ry, Rz, Q, U, V, X, W, Linker, L1, L2, L3, and n apply to any one of formulae (i), (II), (III), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), the same as if each and every embodiment were specifically and individually listed. It is also understood and described that all such embodiments may be used in any of the pharmaceutical compositions, methods, kits, uses, etc. comprising such compounds or other aspects detailed herein.
[0021] As shown in working examples, compounds embraced by Formula (I′) and Formula (I) inhibit the activity or promote the degradation of at least one of PIP4K2A, PIP4K2B, and PIP4K2C. In some embodiments, compounds embraced by Formula (I′) and Formula (I) inhibit the activity or promote the degradation of PIP4K2C.
[0022] Without intending to be bound by any particular theory, the compounds of Formula (IV) and any related formula as applicable such as, e.g., (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), are believed to cause degradation of at least one of PIP4K2A, PIP4K2B, and PIP4K2C by recruitment of cells' Ubiquitin / Proteasome System, whose function is to routinely identify and remove damaged proteins, into close proximity with PIP4K2A, PIP4K2B, or PIP4K2C as a result of binding between PIP4K2A, PIP4K2B, or PIP4K2C, and the targeting ligand. After destruction of a PIP4K2A, PIP4K2B, or PIP4K2C protein, the degrader is released and continues to be active. Thus, by engaging and exploiting the body's own natural protein disposal system, the compounds of the present invention may represent a potential improvement over current small molecule inhibitors of PIP4K2A, PIP4K2B, and PIP4K2C and may overcome one or more limitations regarding their use. Therefore, effective intracellular concentrations of the degraders may be significantly lower than for small molecule PIP4K2A, PIP4K2B, or PIP4K2C inhibitors. Also, although PIP4K2A, PIP4K2B, and / or PIP4K2C genetic knockdown or knockout can be used to reduce the cellular concentration or amount of these proteins, it may be preferable to post-translationally disrupt, degrade, or destabilize PIP4K2A, PIP4K2B, and / or PIP4K2C proteins. Targeting proteins directly, rather than via the DNA or mRNA molecules that encode them, is a more direct and rapid method for reducing the scaffolding function of PIP4K proteins. Hence, degradation can allow some PIP4K2A, PIP4K2B, and / or PIP4K2C catalytic function to proceed while reducing the non-catalytic functions such as scaffolding between PIP4K2A, PIP4K2B, and / or PIP4K2C proteins and other cellular proteins and structures. Collectively, the present compounds may represent a set of new chemical tools for at least one of PIP4K2A, PIP4K2B, and PIP4K2C knockdown and may provide a potential treatment modality for PIP4K2A, PIP4K2B, and / or PIP4K2C-associated cancers and autophagy-dependent diseases (e.g., neurodegenerative disorders, insulin). In some instances, the present compounds may represent a set of new chemical tools for PIP4K2C knockdown and may provide a potential treatment modality for PIP4K2C-associated cancers and autophagy-dependent diseases (e.g., neurodegenerative disorders, insulin). The compounds may be used to enhance immune functions as described in, e.g., US20220168402A1 and Wang et al., Cell Rep. 27:1991-2001 (2019), each of which is incorporated herein by reference in its entirety. Inhibitors and degraders of PIP4K protein and methods for treating diseases or conditions by modulating the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C are also disclosed in WO 2022 / 246025, herein incorporated by reference in its entirety.BRIEF DESCRIPTION OF THE FIGURES
[0023] FIG. 1 shows modulation of phagocytosis by Compound U. The degradation of PIP4K2C by Compound U in human dendritic cells enhanced their phagocytosis of E. coli bioparticles, emphasizing the intrinsic immunological benefits of PIP4K2C targeting in myeloid cells.
[0024] FIG. 2A shows the ability of Compound U to reduce tumor growth in the mouse syngeneic colorectal cancer model MC38-OVA. A marked reduction in tumor growth was observed in the treated group when compared to the vehicle control group. FIG. 2B shows the survival of the mice treated with Compound U and mice treated with the vehicle control.
[0025] FIG. 3 shows that degradation of PIP4K2C by Compound U enhances phagocytosis of E. coli bioparticles in human dendritic cells. The enhanced phagocytosis effect is not seen when using a PIP4K2C inhibitor compound that does not cause degradation, demonstrating the unique impact of a degrader of PIP4K2C over an inhibitory compound alone.
[0026] FIG. 4 shows that degradation of PIP4K2C by Compound U in dendritic cells leads to an increased uptake of dying tumor-derived material, adding to the enhanced engulfment of PIP4K2C-deficient tumor cells by immune cells.
[0027] FIG. 5A shows that Compound U degrades endogenous PIP4K2C in vivo in rats.
[0028] FIG. 5B shows that Compound U degrades endogenous PIP4K2C in vivo in dogs.DETAILED DESCRIPTIONDefinitions
[0029] For use herein, unless clearly indicated otherwise, use of the terms “a”, “an” and the like refers to one or more.
[0030] Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, “about X” includes and describes “X” per se.
[0031] “Alkyl” as used herein refers to and includes, unless otherwise stated, a saturated linear (i.e., unbranched) or branched univalent hydrocarbon chain or combination thereof, having the number of carbon atoms designated (i.e., C1-10 means one to ten carbon atoms). Particular alkyl groups are those having 1 to 10 carbon atoms (a “C1-C10 alkyl”), having 6 to 10 carbon atoms (a “C6-C10 alkyl”), having 1 to 6 carbon atoms (a “C1-C6 alkyl”), having 2 to 6 carbon atoms (a “C2-C6 alkyl”), or having 1 to 4 carbon atoms (a “C1-C4 alkyl”). Particular C1-C4 alkyl groups include C1-C3 alkyl groups. Examples of alkyl groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.
[0032] “Alkylene” as used herein refers to the same residues as alkyl, but having bivalency. Particular alkylene groups are those having 1 to 10 carbon atoms (a “C1-C10 alkylene”), having 6 to 10 carbon atoms (a “C6-C10 alkylene”), having 1 to 6 carbon atoms (a “C1-C6 alkylene”), 1 to 5 carbon atoms (a “C1-C5 alkylene”), 1 to 4 carbon atoms (a “C1-C4 alkylene”) or 1 to 3 carbon atoms (a “C1-C3 alkylene”). Examples of alkylene include, but are not limited to, groups such as methylene (—CH2—), ethylene (—CH2CH2—), propylene (—CH2CH2CH2—), isopropylene (—CH2CH(CH3)—), butylene (—CH2(CH2)2CH2—), isobutylene (—CH2CH(CH3)CH2—), pentylene (—CH2(CH2)3CH2—), hexylene (—CH2(CH2)4CH2—), heptylene (—CH2(CH2)5CH2—), octylene (—CH2(CH2)6CH2—), and the like.
[0033] “Carbocyclyl” as used herein refers to and includes, unless otherwise stated, saturated and partially unsaturated hydrocarbon structures, having the number of carbon atoms designated (i.e., C3-C10 means three to ten carbon atoms). Cycloalkyl can consist of one ring (e.g., cyclohexyl), or multiple rings (e.g., adamantyl). In polycyclic ring systems, one or more of the fused rings can be carbocyclyl or aryl (e.g., spiro[4.5]decanyl, or 1,2,3,4-tetrahydronaphthalenyl), but excludes heterocyclyl or heteroaryl groups. A carbocyclyl comprising more than one ring may be fused, spiro or bridged, or combinations thereof. Particular carbocyclyl groups are those having from 3 to 12 annular carbon atoms (a “C3-12 carbocyclyl”), having 3 to 10 annular carbon atoms (a “C3-10 carbocyclyl”), having 3 to 8 annular carbon atoms (a “C3-C8 carbocyclyl”), having 3 to 6 annular carbon atoms (a “C3-C6 carbocyclyl”), or having from 3 to 4 annular carbon atoms (a “C3-C4 carbocyclyl”). A carbocyclyl group having more than one ring where at least one ring is aromatic may be connected to the parent structure at either an aromatic ring position or at a non-aromatic ring position. In one variation, a carbocyclyl group having more than one ring where at least one ring is aromatic is connected to the parent structure at an aromatic ring position. In another variation, a carbocyclyl group having more than one ring where at least one ring is aromatic is connected to the parent structure at a non-aromatic ring position.
[0034] “Cycloalkyl” as used herein refers to and includes, unless otherwise stated, saturated cyclic hydrocarbon structures, having the number of carbon atoms designated (i.e., C3-C10 means three to ten carbon atoms). Cycloalkyl can consist of one ring (e.g., cyclohexyl), or multiple rings (e.g., adamantyl). In polycyclic ring systems, one or more of the fused rings can be cycloalkyl or aryl (e.g., spiro[4.5]decanyl, or 1,2,3,4-tetrahydronaphthalenyl), but excludes heterocyclyl or heteroaryl groups. A cycloalkyl comprising more than one ring may be fused, spiro or bridged, or combinations thereof. Particular cycloalkyl groups are those having from 3 to 12 annular carbon atoms (a “C3-12 cycloalkyl”), having 3 to 10 annular carbon atoms (a “C3-10 cycloalkyl”), having 3 to 8 annular carbon atoms (a “C3-C5 cycloalkyl”), having 3 to 6 annular carbon atoms (a “C3-C6 cycloalkyl”), or having from 3 to 4 annular carbon atoms (a “C3-C4 cycloalkyl”). Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like. A cycloalkyl group having more than one ring where at least one ring is aromatic may be connected to the parent structure at either an aromatic ring position or at a non-aromatic ring position. In one variation, a cycloalkyl group having more than one ring where at least one ring is aromatic is connected to the parent structure at an aromatic ring position. In another variation, a cycloalkyl group having more than one ring where at least one ring is aromatic is connected to the parent structure at a non-aromatic ring position.
[0035] “Aryl” or “Ar” as used herein refers to an unsaturated aromatic carbocyclic group having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings must be aromatic. Particular aryl groups are those having from 6 to 14 annular carbon atoms (a “C6-C14 aryl”).
[0036] “Heteroaryl” as used herein refers to an unsaturated aromatic cyclic group having from 1 to 14 annular carbon atoms and at least one annular heteroatom, including but not limited to heteroatoms such as nitrogen, oxygen and sulfur. A heteroaryl group may have a single ring (e.g., pyridyl, furyl) or multiple condensed rings (e.g., indolizinyl, benzothienyl) which condensed rings must be aromatic. Particular heteroaryl groups are 5 to 14-membered rings having 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 5 to 10-membered rings having 1 to 8 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, or 5, 6 or 7-membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In one variation, particular heteroaryl groups are monocyclic aromatic 5-, 6- or 7-membered rings having from 1 to 6 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In another variation, particular heteroaryl groups are polycyclic aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. A heteroaryl group may be connected to the parent structure at a ring carbon atom or a ring heteroatom.
[0037] “Heterocycle”, “heterocyclic”, or “heterocyclyl” as used herein refers to a saturated or partially unsaturated non-aromatic cyclic group having a single ring or multiple condensed rings, and having from 1 to 14 annular carbon atoms and from 1 to 6 annular heteroatoms, such as nitrogen, sulfur or oxygen, and the like. A heterocycle comprising more than one ring may be fused, bridged or spiro, or any combination thereof. In fused ring systems, one or more of the fused rings can be cycloalkyl, aryl, or heteroaryl groups. The heterocyclyl group may be optionally substituted independently with one or more substituents described herein. Particular heterocyclyl groups are 3 to 14-membered rings having 1 to 13 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 12-membered rings having 1 to 11 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 10-membered rings having 1 to 9 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 8-membered rings having 1 to 7 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, or 3 to 6-membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In one variation, heterocyclyl includes monocyclic 3-, 4-, 5-, 6- or 7-membered rings having from 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6 annular carbon atoms and 1 to 2, 1 to 3, or 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In another variation, heterocyclyl includes polycyclic non-aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. A heterocyclyl group having more than one ring where at least one ring is aromatic may be connected to the parent structure at either an aromatic ring position or at a non-aromatic ring position. In one variation, a heterocyclyl group having more than one ring where at least one ring is aromatic is connected to the parent structure at an aromatic ring position. In another variation, a heterocyclyl group having more than one ring where at least one ring is aromatic is connected to the parent structure at a non-aromatic ring position.
[0038] “Halo” or “halogen” refers to elements of the Group 7 of the periodic table. Preferred halo groups include fluorine, chlorine, bromine and iodine. Where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached, e.g., dihaloaryl, dihaloalkyl, trihaloaryl etc. refer to aryl and alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be but are not necessarily the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl. An alkyl group in which each hydrogen is replaced with a halo group is referred to as a “perhaloalkyl.” A preferred perhaloalkyl group is trifluoromethyl (—CF3). Similarly, “perhaloalkoxy” refers to an alkoxy group in which a halogen takes the place of each H in the hydrocarbon making up the alkyl moiety of the alkoxy group. An example of a perhaloalkoxy group is trifluoromethoxy (—OCF3).
[0039] “Carbonyl” refers to the group C═O.
[0040] “Oxo” refers to the moiety ═O.
[0041] “Optionally substituted” unless otherwise specified means that a group may be unsubstituted or substituted with one or more (e.g., 1, 2, 3, 4 or 5) of the substituents listed for that group in which the substituents may be the same of different. In one embodiment, an optionally substituted group has one substituent. In another embodiment, an optionally substituted group has two substituents. In another embodiment, an optionally substituted group has three substituents. In another embodiment, an optionally substituted group has four substituents. In some embodiments, an optionally substituted group has 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, or 2 to 5 substituents. In one embodiment, an optionally substituted group is unsubstituted.
[0042] It is understood that aspects and embodiments described herein as “comprising” include “consisting of” and “consisting essentially of” embodiments.
[0043] The term “pharmaceutically acceptable salt”, as used herein, of a given compound refers to salts that retain the biological effectiveness and properties of the given compound and which are not biologically or otherwise undesirable. “Pharmaceutically acceptable salts” include, for example, salts with inorganic acids, and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. See, e.g., Handbook of Pharmaceutical Salts Properties, Selection, and Use, International Union of Pure and Applied Chemistry, John Wiley & Sons (2008), which is incorporated herein by reference. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids. Salts derived from inorganic acids include, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include, e.g., acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, trifluoroacetic acid, and the like. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
[0044] Some of the compounds provided herein may exist as tautomers. Tautomers are in equilibrium with one another. By way of illustration, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown and regardless of the nature of the equilibrium among tautomers, the compounds of this disclosure are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, for example, amide-containing compounds are understood to include their imidic acid tautomers. Likewise, imidic-acid containing compounds are understood to include their amide tautomers.
[0045] The compounds of the present disclosure, or their pharmaceutically acceptable salts, may include an asymmetric center and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- (or as (D)- or (L)- for amino acids). The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms and mixtures thereof in any ratio. Optically active (+) and (−), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or may be resolved using conventional techniques, for example, chromatography and / or fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or the resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC), and chiral supercritical fluid chromatography (SFC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless specified otherwise, it is intended that the present disclosure includes both E and Z geometric isomers. Likewise, cis- and trans- are used in their conventional sense to describe relative spatial relationships.
[0046] A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds, but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers, or mixtures thereof (e.g., racemic mixtures), and includes “enantiomers,” which refers to two stereoisomers whose structures are non-superimposable mirror images of one another. “Diastereomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror images of each other. Where enantiomeric and / or diastereomeric forms exist of a given structure, flat bonds indicate that all stereoisomeric forms of the depicted structure may be present, e.g.,Where enantiomeric and / or diastereomeric forms exist of a given structure, unless indicated otherwise, wedged or hashed bonds without “R”, “S”, or “abs” indicate the composition is made up of at least 90% by weight of a mixture of isomers with known relative stereochemistry, e.g.,Where enantiomeric and / or diastereomeric forms exist of a given structure, wedged or hashed bonds with “R”, “S”, or “abs” indicate the composition is made up of at least 90% by weight of a single enantiomer or diastereomer with known absolute stereochemistry, e.g.,In some instances, diastereomeric mixtures are designated using “r” and / or “s” configurations. In such instances, relative stereochemistry is designated by lowercase (“r” or “s”), and absolute stereochemistry is designated by uppercase (“R” or “S”).The term “disease” as used herein is regarded as a state of health of a subject, wherein the subject cannot maintain homeostasis, and / or wherein, if the disease is not ameliorated, then the subject's health further deteriorates. In contrast, a “disorder” in a subject is a state of health in which the subject is able to maintain homeostasis, but the subject's health is less favorable than it in the absence of the disorder. A disorder does not necessarily cause a further decrease in the subject's health, when left untreated.The term “subject” (or “patient”) as used herein includes mammals prone to or suffering from the indicated disease or disorder e.g., a human or a non-human mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a companion animal such as dogs and cats; in some embodiments, the subject is a livestock animal such as cows, horses, sheep, goats, and pigs; in some embodiments, the subject may be other domesticated and wild animals. A subject “in need of” treatment according to the present invention may be “suffering from or suspected of suffering from” a specific disease or disorder; may have been positively diagnosed with the disease or disorder; or otherwise presents with a sufficient number of risk factors or combination of symptoms such that a medical professional could diagnose the subject with the disease or disorder or suspect that the subject was suffering from the disease or disorder.As used herein, the term, “therapeutically effective amount” is an amount of a compound, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing; or a composition including a compound, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, which is effective in yielding the desired therapeutic response in a particular subject in need thereof. Therefore, the term “therapeutically effective amount” includes the amount of a compound, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, that when administered, induces an improvement in the disease or disorder to be treated, or is sufficient to prevent or slow development or progression of the disease or disorder, or alleviate to some extent one or more of the symptoms of the disease or disorder being treated in a subject, or kills or inhibits the growth of diseased cells (e.g., cancer cells, or autophagy-dependent disease cells), or reduces the amount of at least one of PIP4K2A, PIP4K2B, and PIP4K2C (e.g., reduces the amount of at least PIP4K2C) in diseased cells.
[0051] As used herein, the term “neurodegenerative diseases and disorders” refers to conditions characterized by progressive degeneration and / or death of nerve cells, including problems with movement or mental functioning. Representative examples include Alzheimer's disease (AD) and related dementias, Parkinson's disease (PD) and related dementias, prion disease, motor neuron diseases (MND), Huntington's disease (HD), Pick's syndrome, spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), primary progressive aphasia (PPA), amyotrophic lateral sclerosis (ALS), traumatic brain injury (TBI), multiple sclerosis (MS), and other dementias (e.g., vascular dementia (VaD), Lewy body dementia (LBD), semantic dementia, and frontotemporal lobar dementia (FTD)).
[0052] As used herein, the term “autoimmune disease” refers to conditions where the immune system produces antibodies that attack normal body tissues. Representative examples of autoimmune diseases include, without limitation, autoimmune hematological disorders (e.g., hemolytic anemia, aplastic anemia, anhidrotic ectodermal dysplasia, pure red cell anemia and idiopathic thrombocytopenia), Sjogren's syndrome, Hashimoto thyroiditis, rheumatoid arthritis, juvenile (type 1) diabetes, polymyositis, scleroderma, Addison's disease, lupus including systemic lupus erythematosus, vitiligo, pernicious anemia, glomerulonephritis, pulmonary fibrosis, celiac disease, polymyalgia rheumatica, multiple sclerosis, ankylosing spondylitis, alopecia areata, vasculitis, autoimmune uveoretinitis, lichen planus, bullous pemphigus, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, myasthenia gravis, immunoglobulin A nephropathy, Wegener granulomatosis, autoimmune oophoritis, sarcoidosis, rheumatic carditis, ankylosing spondylitis, Grave's disease, autoimmune thrombocytopenic purpura, psoriasis, psoriatic arthritis, dermatitis herpetiformis, ulcerative colitis, and temporal arteritis, and the like.
[0053] As used herein, the term “cell proliferative disease or disorder” refers to a condition characterized by dysregulated or abnormal cell growth, or both, including noncancerous conditions such as neoplasms, precancerous conditions, benign tumors, and cancer.
[0054] As used herein, “cell proliferative diseases or disorders of the hematological system” include lymphoma, leukemia, myeloid neoplasms, mast cell neoplasms, myelodysplasia, benign monoclonal gammopathy, lymphomatoid papulosis, polycythemia vera, chronic myelocytic leukemia, agnogenic myeloid metaplasia, and essential thrombocythemia. Representative examples of hematologic cancers may thus include multiple myeloma, lymphoma (including T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma (diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and ALK+ anaplastic large cell lymphoma (e.g., B-cell non-Hodgkin's lymphoma selected from diffuse large B-cell lymphoma (e.g., germinal center B-cell-like diffuse large B-cell lymphoma or activated B-cell-like diffuse large B-cell lymphoma), Burkitt's lymphoma / leukemia, mantle cell lymphoma, mediastinal (thymic) large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia, metastatic pancreatic adenocarcinoma, refractory B-cell non-Hodgkin's lymphoma, and relapsed B-cell non-Hodgkin's lymphoma, childhood lymphomas, and lymphomas of lymphocytic and cutaneous origin, e.g., small lymphocytic lymphoma, leukemia, including childhood leukemia, hairy-cell leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloid leukemia (e.g., acute monocytic leukemia), chronic lymphocytic leukemia, small lymphocytic leukemia, chronic myelocytic leukemia, chronic myelogenous leukemia, and mast cell leukemia, myeloid neoplasms and mast cell neoplasms.
[0055] As used herein, “cell proliferative diseases or disorders of the liver” include all forms of cell proliferative disorders affecting the liver. Cell proliferative disorders of the liver may include liver cancer (e.g., hepatocellular carcinoma, intrahepatic cholangiocarcinoma and hepatoblastoma), a precancer or precancerous condition of the liver, benign growths or lesions of the liver, and malignant growths or lesions of the liver, and metastatic lesions in tissue and organs in the body other than the liver. Cell proliferative disorders of the liver may include hyperplasia, metaplasia, and dysplasia of the liver.
[0056] As used herein, “cell proliferative diseases or disorders of the brain” include all forms of cell proliferative disorders affecting the brain. Cell proliferative disorders of the brain may include brain cancer (e.g., gliomas, glioblastomas, meningiomas, pituitary adenomas, vestibular schwannomas, and primitive neuroectodermal tumors (medulloblastomas)), a precancer or precancerous condition of the brain, benign growths or lesions of the brain, and malignant growths or lesions of the brain, and metastatic lesions in tissue and organs in the body other than the brain. Cell proliferative disorders of the brain may include hyperplasia, metaplasia, and dysplasia of the brain.
[0057] As used herein, “cell proliferative diseases or disorders of the lung” include all forms of cell proliferative disorders affecting lung cells. Cell proliferative disorders of the lung include lung cancer, precancer and precancerous conditions of the lung, benign growths or lesions of the lung, hyperplasia, metaplasia, and dysplasia of the lung, and metastatic lesions in the tissue and organs in the body other than the lung. Lung cancer includes all forms of cancer of the lung, e.g., malignant lung neoplasms, carcinoma in situ, typical carcinoid tumors, and atypical carcinoid tumors. Lung cancer includes small cell lung cancer (“SLCL”), non-small cell lung cancer (“NSCLC”), adenocarcinoma, small cell carcinoma, large cell carcinoma, squamous cell carcinoma, and mesothelioma. Lung cancer can include “scar carcinoma”, bronchoalveolar carcinoma, giant cell carcinoma, spindle cell carcinoma, and large cell neuroendocrine carcinoma. Lung cancer also includes lung neoplasms having histologic and ultrastructural heterogeneity (e.g., mixed cell types). In some embodiments, a compound treats non-metastatic or metastatic lung cancer (e.g., NSCLC, ALK-positive NSCLC, NSCLC harboring ROS1 rearrangement, lung adenocarcinoma, and squamous cell lung carcinoma).
[0058] As used herein, “cell proliferative diseases or disorders of the colon” include all forms of cell proliferative disorders affecting colon cells, including colon cancer, a precancer or precancerous conditions of the colon, adenomatous polyps of the colon and metachronous lesions of the colon. Colon cancer includes sporadic and hereditary colon cancer, malignant colon neoplasms, carcinoma in situ, typical carcinoid tumors, and atypical carcinoid tumors, adenocarcinoma, squamous cell carcinoma, and squamous cell carcinoma. Colon cancer can be associated with a hereditary syndrome such as hereditary nonpolyposis colorectal cancer, familiar adenomatous polyposis, MYH associated polyposis, Gardner's syndrome, Peutz-Jeghers syndrome, Turcot's syndrome and juvenile polyposis. Cell proliferative disorders of the colon may also be characterized by hyperplasia, metaplasia, or dysplasia of the colon.
[0059] As used herein, “cell proliferative diseases or disorders of the pancreas” include all forms of cell proliferative disorders affecting pancreatic cells. Cell proliferative disorders of the pancreas may include pancreatic cancer, a precancer or precancerous condition of the pancreas, hyperplasia of the pancreas, dysplasia of the pancreas, benign growths or lesions of the pancreas, and malignant growths or lesions of the pancreas, and metastatic lesions in tissue and organs in the body other than the pancreas. Pancreatic cancer includes all forms of cancer of the pancreas, including ductal adenocarcinoma, adenosquamous carcinoma, pleomorphic giant cell carcinoma, mucinous adenocarcinoma, osteoclast-like giant cell carcinoma, mucinous cystadenocarcinoma, acinar carcinoma, unclassified large cell carcinoma, small cell carcinoma, pancreatoblastoma, papillary neoplasm, mucinous cystadenoma, papillary cystic neoplasm, and serous cystadenoma, and pancreatic neoplasms having histologic and ultrastructural heterogeneity (e.g., mixed cell).
[0060] As used herein, “cell proliferative diseases or disorders of the prostate” include all forms of cell proliferative disorders affecting the prostate. Cell proliferative disorders of the prostate may include prostate cancer, a precancer or precancerous condition of the prostate, benign growths or lesions of the prostate, and malignant growths or lesions of the prostate, and metastatic lesions in tissue and organs in the body other than the prostate. Cell proliferative disorders of the prostate may include hyperplasia, metaplasia, and dysplasia of the prostate.
[0061] As used herein, “cell proliferative diseases or disorders of the ovary” include all forms of cell proliferative disorders affecting cells of the ovary. Cell proliferative disorders of the ovary may include a precancer or precancerous condition of the ovary, benign growths or lesions of the ovary, ovarian cancer, and metastatic lesions in tissue and organs in the body other than the ovary. Cell proliferative disorders of the ovary may include hyperplasia, metaplasia, and dysplasia of the ovary.
[0062] As used herein, “cell proliferative diseases or disorders of the breast” include all forms of cell proliferative disorders affecting breast cells. Cell proliferative disorders of the breast may include breast cancer, a precancer or precancerous condition of the breast, benign growths or lesions of the breast, and metastatic lesions in tissue and organs in the body other than the breast. Cell proliferative disorders of the breast may include hyperplasia, metaplasia, and dysplasia of the breast.
[0063] As used herein, “cell proliferative diseases or disorders of the skin” include all forms of cell proliferative disorders affecting skin cells. Cell proliferative disorders of the skin may include a precancer or precancerous condition of the skin, benign growths or lesions of the skin, melanoma, malignant melanoma or other malignant growths or lesions of the skin, and metastatic lesions in tissue and organs in the body other than the skin. Cell proliferative disorders of the skin may include hyperplasia, metaplasia, and dysplasia of the skin.
[0064] As used herein, “cell proliferative diseases or disorders of the endometrium” include all forms of cell proliferative disorders affecting cells of the endometrium. Cell proliferative disorders of the endometrium may include a precancer or precancerous condition of the endometrium, benign growths or lesions of the endometrium, endometrial cancer, and metastatic lesions in tissue and organs in the body other than the endometrium. Cell proliferative disorders of the endometrium may include hyperplasia, metaplasia, and dysplasia of the endometrium.
[0065] In some embodiments, the cancer is a hematological cancer e.g., leukemia, lymphoma or multiple myeloma.Compounds of Formula (I′) or (I)
[0066] In one aspect, provided is a compound of Formula (I′)or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:R is halo;Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b;
[0069] Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b;
[0070] Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1;
[0071] V is a bond, —C1-4alkylene-, —C(O)—, —C(O)O-#, —OC(O)#—C1-4alkylene-C(O)-#, —C(O)N(RV)-#, —N(RV)C(O)-#, —OC(O)N(RV)-#, —N(RV)—C(O)O#, —C1-4alkylene-C(O)N(R)-# or —C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and
[0072] Q is RQ, or Ring 5,
[0073] wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more Rb;
[0074] or
[0075] Q is of Formula (i)wherein:Ring A is selected from the group consisting of each of which is optionally substituted with one or more C1-4alkyl or halo;X is a bond, —O—, —NH—, or —NHC(O)—;Ring B is selected from the group consisting of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RD is H or C1-4alkyl, wherein # indicates attachment to X;W is a bond, —O—, —NH—, or —NHC(O)—;Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC;Linker is a bond, —O—, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)—C1-10alkylene, C1-6alkylene-C(O)N(Ry)—C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein* indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent;
[0084] L1 is a bond or C1-6 alkylene;
[0085] L2 is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; and
[0086] L3 is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)—C1-10alkylene, C(O)—C1-10alkylene-N(Ry), C(O)N(Ry)—C1-10alkylene, or C(O)N(Ry)—C1-10alkylene-N(Ry);
[0087] U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present;
[0088] Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b;
[0089] each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl;
[0090] each R2a, R3a, R4a, and R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo;
[0091] each R2b, R3b, R4b, and R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx;
[0092] each RC is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0093] each RL is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0094] each RQ is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0095] each RV is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0096] each Rw is independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4 hydroxyalkyl, or C1-4aminoalkyl;
[0097] each Rx is independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl;
[0098] each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and
[0099] each n is independently 0, 1, or 2;wherein:
[0100] (a) Ring 1 comprises an intraannular amide, or
[0101] (b) V comprises an amide or carbamate, or
[0102] (c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide or carbamate;and wherein:
[0103] when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl;and wherein:
[0104] when Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, Q is RQ, and V is —OC(O)#, then RQ is not tert-butyl.
[0105] In one aspect, provided is a compound of Formula (I′)or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:R is halo;Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b;
[0108] Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b;
[0109] Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1;
[0110] V is a bond, —C1-4alkylene-, —C(O)—, —C(O)O-#, —OC(O)#—C1-4alkylene-C(O)-#, —C(O)N(RV)-#, —N(RV)C(O)-#, —OC(O)N(RV)-#, —N(RV)—C(O)O #, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and
[0111] Q is RQ, or Ring 5,
[0112] wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b;
[0113] or
[0114] Q is of Formula (i)wherein:Ring A is selected from the group consisting of each of which is optionally substituted with one or more C1-4alkyl or halo;X is a bond, —O—, —NH—, or —NHC(O)—;Ring B is selected from the group consisting of each of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RD is H or C1-4alkyl, wherein # indicates attachment to X;W is a bond, —O—, —NH—, or —NHC(O)—;Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC;Linker is a bond, —O—, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)—C1-10alkylene, C1-6alkylene-C(O)N(Ry)—C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein* indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent;
[0123] L1 is a bond or C1-6 alkylene;
[0124] L2 is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; and
[0125] L3 is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)—C1-10alkylene, C(O)—C1-10alkylene-N(Ry), C(O)N(Ry)—C1-10alkylene, or C(O)N(Ry)—C1-10alkylene-N(Ry);
[0126] U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present;
[0127] Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b;
[0128] each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)1—C1-4alkyl;
[0129] each R2a, R3a, R4a, and R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo;
[0130] each R2b, R3b, R4b, and R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx;
[0131] each RC is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0132] each RL is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0133] each RQ is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0134] each RV is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0135] each Rw is independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1. 4hydroxyalkyl, or C1-4aminoalkyl;
[0136] each Rx is independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)a—C1-4alkyl;
[0137] each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n—C1-4alkyl; and
[0138] each n is independently 0, 1, or 2;wherein:
[0139] (a) Ring 1 comprises an intraannular amide, or
[0140] (b) V comprises an amide or carbamate, or
[0141] (c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide or carbamate;and wherein:
[0142] when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.
[0143] In one aspect, provided is a compound of Formula (I):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:R is halo;Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b;
[0146] Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b;
[0147] Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1, wherein each 4- to 8-membered heterocyclyl of Ring 1 comprises at least one heteroatom selected from N and O;
[0148] V is a bond, —C1-4alkylene-, —C(O)—, —C1-4alkylene-C(O)-#, —C(O)N(RV)-#, —N(RV)C(O)-#, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and
[0149] Q is RQ, or Ring 5,
[0150] wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b,
[0151] or
[0152] Q is of Formula (i)wherein:Ring A is selected from the group consisting of each of which is optionally substituted with one or more C1-4alkyl or halo;X is a bond, —O—, —NH—, or —NHC(O)—;Ring B is selected from the group consisting of each of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RD is H or C1-4alkyl, wherein # indicates attachment to X;W is a bond, —O—, —NH—, or —NHC(O)—;Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC;Linker is a bond, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)—C1-10alkylene, C1-6alkylene-C(O)N(Ry)—C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein* indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent;
[0161] L1 is a bond or C1-6 alkylene;
[0162] L2 is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; and
[0163] L3 is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)—C1-10alkylene, C(O)—C1-10alkylene-N(Ry), C(O)N(Ry)—C1-10alkylene, or C(O)N(Ry)—C1-10alkylene-N(Ry);
[0164] U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present;
[0165] Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b;
[0166] each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl;
[0167] each R2a, R3a, R4a, and R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)aN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo;
[0168] each R2b, R3b, R4b, and R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx;
[0169] each RC is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0170] each RL is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0171] each RQ is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0172] each RV is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0173] each Rx is independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl;
[0174] each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and
[0175] each n is independently 0, 1, or 2;wherein:
[0176] (a) Ring 1 comprises an intraannular amide, or
[0177] (b) V comprises an amide, or
[0178] (c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide;and wherein:
[0179] when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl;and wherein:
[0180] when Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, Q is RQ, and V is —OC(O)#, then RQ is not tert-butyl.
[0181] In one aspect, provided is a compound of Formula (I):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:R is halo;Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b;
[0184] Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b;
[0185] Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1, wherein each 4- to 8-membered heterocyclyl of Ring 1 comprises at least one heteroatom selected from N and O;
[0186] V is a bond, —C1-4alkylene-, —C(O)—, —C1-4alkylene-C(O)-#, —C(O)N(RV)-#, —N(RV)C(O)-#, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and
[0187] Q is RQ, or Ring 5,
[0188] wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b;
[0189] or
[0190] Q is of Formula (i)wherein:Ring A is selected from the group consisting of each of which is optionally substituted with one or more C1-4alkyl or halo;X is a bond, —O—, —NH—, or —NHC(O)—;Ring B is selected from the group consisting of each of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RD is H or C1-4alkyl, wherein # indicates attachment to X;W is a bond, —O—, —NH—, or —NHC(O)—;Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC;Linker is a bond, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)—C1-10alkylene, C1-6alkylene-C(O)N(Ry)—C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein* indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent;
[0199] L1 is a bond or C1-6 alkylene;
[0200] L2 is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; and
[0201] L3 is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)—C1-10alkylene, C(O)—C1-10alkylene-N(Ry), C(O)N(Ry)—C1-10alkylene, or C(O)N(Ry)—C1-10alkylene-N(Ry);
[0202] U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present;
[0203] Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b;
[0204] each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl;
[0205] each R2a, R3a, R4a, and R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo;
[0206] each R2b, R3b, R4b, and R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx;
[0207] each RC is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0208] each RL is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0209] each RQ is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0210] each RV is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0211] each Rx is independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl;
[0212] each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl; and
[0213] each n is independently 0, 1, or 2;wherein:
[0214] (a) Ring 1 comprises an intraannular amide, or
[0215] (b) V comprises an amide, or
[0216] (c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide;and wherein:
[0217] when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.
[0218] In one aspect, provided is a compound of Formula (I):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:R is halo;Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b;
[0221] Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b;
[0222] Ring 1 is a 4- to 8-membered cycloalkyl, saturated 4- to 8-membered heterocyclyl comprising at least one annular ether or annular amine, or saturated 4- to 8-membered heterocyclyl comprising an annular amide, each of which is optionally substituted with one or more R1;
[0223] V is a bond, —C1-4alkylene-, —C(O)—, —C1-4alkylene-C(O)-#, —C(O)N(RV)-#, —N(RV)C(O)-#, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; and
[0224] Q is RQ, or Ring 5,
[0225] wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b
[0226] or
[0227] Q is of Formula (i)wherein:Ring A is selected from the group consisting of each of which is optionally substituted with one or more C1-4alkyl or halo;X is a bond, —O—, —NH—, or —NHC(O)—;Ring B is selected from the group consisting of each of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RD is H or C1-4alkyl, wherein # indicates attachment to X;W is a bond, —O—, —NH—, or —NHC(O)—;Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC;Linker is a bond, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)—C1-10alkylene, C1-6alkylene-C(O)N(Ry)—C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein* indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent;
[0236] L1 is a bond or C1-6 alkylene;
[0237] L2 is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; and
[0238] L3 is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)—C1-10alkylene, C(O)—C1-10alkylene-N(Ry), C(O)N(Ry)—C1-10alkylene, or C(O)N(Ry)—C1-10alkylene-N(Ry);
[0239] U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present;
[0240] Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b;
[0241] each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)1—C1-4alkyl;
[0242] each R2a, R3a, R4a, and R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo;
[0243] each R2b, R3b, R4b, and R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx;
[0244] each RC is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0245] each RL is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0246] each RQ is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0247] each RV is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0248] each Rx is independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl;
[0249] each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and
[0250] each n is independently 0, 1, or 2;wherein:
[0251] (i) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amine, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is —C(O)— or —C1-4alkylene-C(O)-#; and
[0252] (ii) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amide, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is a bond or —C1-4alkylene-; and
[0253] (iii) when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then:
[0254] (a) V is —C(O)N(RV)-#, —N(RV)C(O)-#, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#; or
[0255] (b) Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5; or
[0256] (c) Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2;and wherein:
[0257] when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.
[0258] In one aspect, provided is a compound of Formula (I):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:R is halo;Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b;
[0261] Ring 3 is a monocyclic ring selected from the group consisting of 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b;
[0262] Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1, wherein each 4- to 8-membered heterocyclyl of Ring 1 comprises at least one N heteroatom;
[0263] V is a —C(O)—, —C1-4alkylene-C(O)-#, —C(O)N(RV)-#, —N(R′)C(O)-#, or —C1-4alkylene-C(O)N(RV)-#, wherein # indicates the point of attachment to Ring 1; and
[0264] Q is RQ,
[0265] or
[0266] Q is of Formula (i)wherein:Ring A is is optionally substituted with one or more C1-4alkyl or halo;X is a bond, or —NH—;Ring B is selected from the group consisting of each of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RD is H or C1-4alkyl, wherein # indicates attachment to X;W is a bond or —O—;Ring C is optional, and when present is 6-membered heterocyclyl optionally substituted with one or more RC;Linker is a bond, C1-10alkylene, or C(O)C1-10alkylene;U is absent when Ring 2 is absent, and is a bond when Ring 2 is present;Ring 2 is optional, and when present is 6-membered or 11-membered heterocyclyl optionally substituted with one or more R2a;
[0275] each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl;
[0276] each R2a, R3a, and R4a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo;
[0277] each R3b and R4b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx;
[0278] each RC is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0279] each RQ is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0280] each RV is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;
[0281] each Rx is independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O), —C1-4alkyl;
[0282] each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and
[0283] each n is independently 0, 1, or 2;wherein:
[0284] (i) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amine, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is —C(O)— or —C1-4alkylene-C(O)-#; and
[0285] (ii) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at an annular amide, optionally substituted with one or more R1, then V is attached to the annular amide nitrogen atom of Ring 1 and is a bond or —C1-4alkylene-; and
[0286] (iii) when Ring 1 is C4-8 cycloalkyl, optionally substituted with one or more R1, then:
[0287] (a) V is —C(O)N(RV)-# or —N(RV)C(O)-#; or
[0288] (b) Ring 2 is 6- or 11-membered heterocyclyl optionally substituted with one
[0289] or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2;and wherein:
[0290] when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.
[0291] In some embodiments of the compound of Formula (I), R is chloro, fluoro, or bromo. In some embodiments of the compound of Formula (I), R is chloro or fluoro. In some embodiments of the compound of Formula (I), R is chloro. In some embodiments of the compound of Formula (I), R is fluoro.
[0292] In some embodiments of the compound of Formula (I), Ring 1 is a C4-8 cycloalkyl optionally substituted with one or more R1, wherein each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl. In some embodiments, Ring 1 is a C5-8 cycloalkyl optionally substituted with one or more R1. In some embodiments, Ring 1 is a C6-8 cycloalkyl optionally substituted with one or more R1. In some embodiments, Ring 1 is cyclohexyl or spiro[3.3.]heptanyl, each of which is optionally substituted with one or more R1. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1. In some embodiments, Ring 1 isIn some embodiments, Ring 1 isIn some embodiments, Ring 1 isIn some embodiments, Ring 1 isIn some embodiments, Ring 1 isIn some embodiments, Ring 1 isIn some embodiments of the compound of Formula (I), Ring 1 is a saturated 4- to 8-membered heterocyclyl comprising at least one annular ether or annular amine, optionally substituted with one or more R1, wherein each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 5- to 8-membered heterocyclyl comprising at least one annular ether or annular amine, optionally substituted with one or more R1. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 6- to 8-membered heterocyclyl comprising at least one annular ether or annular amine, optionally substituted with one or more R1. In some embodiments, Ring 1 is piperidinyl or 2-azaspiro[3.3]heptanyl, each of which is optionally substituted with one or more R1. In some embodiments, Ring 1 iswherein # indicates attachment to V, each of which is optionally substituted with one or more R1. In some embodiments, Ring 1 iswherein # indicates attachment to V, each of which is optionally substituted with one or more R1. In some embodiments, Ring 1 isIn some embodiments, Ring 1 isIn some embodiments, Ring 1 isIn some embodiments of the compound of Formula (I), Ring 1 is a saturated 4- to 8-membered heterocyclyl comprising an annular amide, optionally substituted with one or more R1, wherein each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl. In some embodiments, Ring 1 isoptionally substituted with one or more R1, wherein # indicates attachment to V. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1. In some embodiments, Ring 1 isIn some embodiments, Ring 1 isIn some embodiments of the compound of Formula (I), Ring 1 is a C4-8 cycloalkyl optionally substituted with one or more R1, wherein each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl; and V is —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments, Ring 1 is a C5-8 cycloalkyl optionally substituted with one or more R1, and V is —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is a C6-8 cycloalkyl optionally substituted with one or more R1, and V is —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is cyclohexyl or spiro[3.3.]heptanyl, each of which is optionally substituted with one or more R1, and V is —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, and V is —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, and V is —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4 alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 isand V is —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 isand V is —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 isand V is —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##.In some embodiments of the compound of Formula (I), Ring 1 is a C4-8 cycloalkyl optionally substituted with one or more R1, wherein each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl; and V is —OC(O)N(RV)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments, Ring 1 is a C5-8 cycloalkyl optionally substituted with one or more R1, and V is —OC(O)N(RV)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is a C6-8 cycloalkyl optionally substituted with one or more R1, and V is —OC(O)N(RV)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4 alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is cyclohexyl or spiro[3.3.]heptanyl, each of which is optionally substituted with one or more R1, and V is —OC(O)N(RV)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4 alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, and V is —OC(O)N(RV)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, and V is —OC(O)N(RV)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 isand V is —OC(O)N(RV)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 isand V is —C(O)N(R)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 isand V is —OC(O)N(RV)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 isand V is —OC(O)N(RV)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 isand V is —OC(O)N(RV)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##.In some embodiments of the compound of Formula (I), Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular ether and no annular amine or annular amide, optionally substituted with one or more R1, wherein each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and V is —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is a 5- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, optionally substituted with one or more R1, and V is —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is a 6- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, optionally substituted with one or more R1, and V is —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##.In some embodiments of the compound of Formula (I), Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular ether and no annular amine or annular amide, optionally substituted with one or more R1, wherein each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O), —C1-4alkyl; and V is —OC(O)N(RV)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is a 5- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, optionally substituted with one or more R1, and V is —OC(O)N(RV)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##. In some embodiments, Ring 1 is a 6- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, optionally substituted with one or more R1, and V is —OC(O)N(RV)-##, —N(RV)—C(O)O##, —C(O)N(RV)-##, —N(RV)C(O)-##, —C1-4alkylene-C(O)N(RV)-## or —C1-4alkylene-N(RV)C(O)-##.In some embodiments of the compound of Formula (I), Ring 1 is a saturated 4- to 8-membered heterocyclyl comprising at least one annular amine and no annular amide, optionally substituted with one or more R1, wherein each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl; and V is —C(O)-## or —C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 5- to 8-membered heterocyclyl comprising at least one annular amine, optionally substituted with one or more R1, and V is —C(O)-## or —C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 6- to 8-membered heterocyclyl comprising at least one or annular amine, optionally substituted with one or more R1, and V is —C(O)-## or —C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments, Ring 1 is piperidinyl or 2-azaspiro[3.3]heptanyl, each of which is optionally substituted with one or more R1, and V is —C(O)-## or —C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, wherein # indicates attachment to V; and V is —C(O)-## or —C1-4alkylene-C(O)-##. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, and V is —C(O)-## or —C1-4alkylene-C(O)-##. In some embodiments, Ring 1 isand V is —C(O)-## or —C1-4alkylene-C(O). In some embodiments, Ring 1 isand V is —C(O)-## or —C1-4alkylene-C(O). In some embodiments, Ring 1 isand V is —C(O)-## or —C1-4alkylene-C(O).In some embodiments of the compound of Formula (I), Ring 1 is a saturated 4- to 8-membered heterocyclyl comprising at least one annular amine and no annular amide, optionally substituted with one or more R1, wherein each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)1—C1-4alkyl; and V is —C(O)O-##, —OC(O)##, —C(O)-## or —C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 5- to 8-membered heterocyclyl comprising at least one annular amine, optionally substituted with one or more R1, and V is —C(O)O-##, —OC(O)##, —C(O)-## or —C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 6- to 8-membered heterocyclyl comprising at least one or annular amine, optionally substituted with one or more R1, and V is —C(O)O-##, —OC(O)##, —C(O)-## or —C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments, Ring 1 is piperidinyl or 2-azaspiro[3.3]heptanyl, each of which is optionally substituted with one or more R1, and V is —C(O)O-##, —OC(O)##, —C(O)-## or —C1-4alkylene-C(O)-##, wherein ## indicates attachment to Ring 1. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, wherein # indicates attachment to V; and V is —OC(O)##, —C(O)-## or —C1-4alkylene-C(O)-##. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, and V is —OC(O)##, —C(O)-## or —C1-4alkylene-C(O)-##. In some embodiments, Ring 1 isand V is —OC(O)##, —C(O)-## or —C1-4alkylene-C(O). In some embodiments, Ring 1 isand V is —OC(O)##, —C(O)-## or —C1-4alkylene-C(O). In some embodiments, Ring 1 isand V is —OC(O)##, —C(O)-## or —C1-4alkylene-C(O).In some embodiments of the compound of Formula (I), Ring 1 is a saturated 4- to 8-membered heterocyclyl comprising an annular amide, optionally substituted with one or more R1, and V is a bond or —C1-4alkylene-. In some embodiments, Ring 1 isoptionally substituted with one or more R1, wherein # indicates attachment to V; and V is a bond or —C1-4alkylene-. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1; and V is a bond or —C1-4alkylene-. In some embodiments, Ring 1 isand V is a bond or —C1-4alkylene-. In some embodiments, Ring 1 isand V is a bond or —C1-4alkylene-.In some embodiments, Ring 1 comprises an intraannular amide, or V comprises an amide, or V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide. In some embodiments, Ring 1 comprises an intraannular amide. In some embodiments, V comprises an amide. In some embodiments, V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide. In some embodiments of Formula (I), (II), (III), or (IV), or a related formula as appropriate, V is taken together with an atom of Ring 1 to which it is attached, to form an amide. In some embodiments of Formula (I) or (II), or a related formula as appropriate, V is taken together with an atom of Ring 5 to which it is attached, to form an amide. In some embodiments of Formula (I) or (IV), or a related formula as appropriate, V is taken together with an atom of Ring 5 to which it is attached, to form an amide.In some embodiments, V comprises a carbamate, or V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form a carbamate. In some embodiments, V comprises a carbamate. In some embodiments, V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form a carbamate. In some embodiments of Formula (I′), (I), (II), (III), or (IV), or a related formula as appropriate, V is taken together with an atom of Ring 1 to which it is attached, to form a carbamate. In some embodiments of Formula (I′), (I), or (II), or a related formula as appropriate, V is taken together with an atom of Ring 5 to which it is attached, to form a carbamate. In some embodiments of Formula (I′), (I), or (IV), or a related formula as appropriate, V is taken together with an atom of Ring 5 to which it is attached, to form a carbamate.In some embodiments, when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amine, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is —C(O)— or —C1-4alkylene-C(O)-#.In some embodiments, when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amine, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is —OC(O)##.In some embodiments, when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amide, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is a bond or —C1-4alkylene-.In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then (a) V is —C(O)N(RV)-#, —N(Ry)C(O)-#, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#; or (b) Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5; or (c) Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2.In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then (a) V is —OC(O)N(RV)-# or —N(RV)—C(O)O #, wherein # indicates attachment to Ring 1; or (b) Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and V is —C(O)O-# and is attached to an annular nitrogen atom of Ring 5, wherein # indicates attachment to Ring 1; or (c) Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, and V is —C(O)O-# and is attached to an annular nitrogen atom of Ring 2, wherein # indicates attachment to Ring 1.In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then V is —C(O)N(RV)-#, —N(RV)C(O)-#, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#.In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then V is —OC(O)N(RV)-# or —N(RV)—C(O)O #, wherein # indicates attachment to Ring 1.In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5.In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and V is —C(O)O-# and is attached to an annular nitrogen atom of Ring 5, wherein # indicates attachment to Ring 1.In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2.In some embodiments, when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, each of which is optionally substituted with one or more R1, then Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, and V is —C(O)O-# and is attached to an annular nitrogen atom of Ring 2, wherein # indicates attachment to Ring 1.In some embodiments of the compound of Formula (I), the compound is of Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w):wherein Q, R, Ring 3, and Ring 4 are as defined herein for Formula (I). In some embodiments, Ring 4 is present.In some embodiments of the compound of Formula (I), the compound is of Formula (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag):wherein Q, R, Ring 3, and Ring 4 are as defined herein for Formula (I). In some embodiments, Ring 4 is present.In some embodiments of the compound of Formula (I), or a related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 3 is phenyl optionally substituted with one or more R3b, and Ring 4 is phenyl optionally substituted with one or more R4b. In some embodiments, the compound is of Formula (I-x),or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein each m is independently an integer from 0 to 4, and Q, V, R, and Ring 1 are as described herein for Formula (I). In some embodiments, each m is independently an integer from 0 to 2. In some embodiments, each m is 0 or 1. In some embodiments, Ring 3 is phenyl, Ring 4 is phenyl, and the compound is of Formula (I-y)or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q, V, R, and Ring 1 are as described herein for Formula (I). In some embodiments of Formula (I-x) or (I-y), Ring 1 is cyclohexyl or piperidinyl, each of which is optionally substituted with one or more R1. In some embodiments, Ring 1 is cyclohexyl or piperidinyl, each of which is optionally substituted with one or more R1, and Q is of Formula (i). In some embodiments, Ring 1 is cyclohexyl or piperidinyl, each of which is optionally substituted with one or more R1, and Q is RQ.In some embodiments, Ring 3 is 5-membered heteroaryl, and Ring 4 is present. In some embodiments, Ring 3 is 5-membered heteroaryl, and Ring 4 is not cycloalkyl or tetrahydropyranyl. In some embodiments, Ring 3 is 5-membered heteroaryl, and Ring 4 is phenyl optionally substituted with one or more R4b, 5- to 6-membered heteroaryl optionally substituted with one or more R4b, or 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, wherein Ring 4 is not tetrahydropyranyl. In some embodiments, Ring 3 is 5-membered heteroaryl, and Ring 4 is phenyl optionally substituted with one or more R4b or 5- to 6-membered heteroaryl optionally substituted with one or more R4b. In some embodiments, Ring 3 is 5-membered heteroaryl, and Ring 4 is 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, wherein Ring 4 is not tetrahydropyranyl.In some embodiments of the compound of Formula (I) or a related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 3 is 5- or 6-membered heterocyclyl optionally substituted with one or more R3a and Ring 4 is phenyl optionally substituted with one or more R4b.In some embodiments of the compound of Formula (I) or a related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 3 is 5- or 6-membered heterocyclyl optionally substituted with one or more R3a and Ring 4 is 5- or 6-membered heteroaryl optionally substituted with one or more R4b.In some embodiments of the compound of Formula (I) or a related formula such as (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 3 is phenyl optionally substituted with one or more R3b, and Ring 4 is 5- or 6-membered heterocyclyl optionally substituted with one or more R4a.In some embodiments of the compound of Formula (I) or a related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 3 is phenyl optionally substituted with one or more R3b, and Ring 4 is 3- to 6-membered cycloalkyl optionally substituted with one or more R4a.In some embodiments of the compound of Formula (I) or a related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (If), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 3 is 5- or 6-membered heteroaryl optionally substituted with one or more R3b, and Ring 4 is phenyl optionally substituted with one or more R4b.In some embodiments of the compound of Formula (I), or related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), and (I-y), Q is H.In some embodiments of the compound of Formula (I), or related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), and (I-y), Q is RQ. In some embodiments, RQ is H, halo, OH, C1-4alkyl, or C1-4haloalkyl. In some embodiments, RQ is halo, OH, C1-4alkyl, or C1-4haloalkyl. In some embodiments, RQ is C1-4alkyl or C1-4haloalkyl. In some embodiments, RQ is C1-2alkyl or C1-2haloalkyl. In some embodiments, RQ is methyl. In some embodiments, RQ is H.In some embodiments of the compound of Formula (I), Q is Ring 5, and the compound is of Formula (II)or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Ring 5, V, Ring 1, R, Ring 3, and Ring 4 are as described for Formula (I). In some embodiments, Ring 4 is present.In some embodiments of the compound of Formula (I), Q is Ring 5, and the compound is of Formula (II)or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:R is halo;Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b;Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b;Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1;V is a bond, —C1-4alkylene-, —C(O)—, —C(O)O-#, —OC(O)#—C1-4alkylene-C(O)-#, —C(O)N(RV)-#, —N(RV)C(O)-#, —OC(O)N(RV)-#, —N(RV)—C(O)O #, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; andRing 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b;each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)1—C1-4alkyl;each R3a, R4a, and R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo;each R3b, R4b, and R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)1Rx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx;each RV is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;each Rw is independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4 hydroxyalkyl, or C1-4aminoalkyl;each Rx is independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl;each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n—C1-4alkyl; andeach n is independently 0, 1, or 2;wherein:(a) Ring 1 comprises an intraannular amide, or(b) V comprises an amide or carbamate, or(c) V is taken together with an atom of Ring 1 or Ring 5 to which it is attached, to form an amide or carbamate;and wherein:when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.In some embodiments of the compound of Formula (I), Q is RQ, and the compound is of Formula (III)or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:R is halo;Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b;Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b;Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1;V is a bond, —C1-4alkylene-, —C(O)—, —C(O)O-#, —OC(O)#—C1-4alkylene-C(O)-#, —C(O)N(RV)-#, —N(RV)C(O)-#, —OC(O)N(RV)-#, —N(RV)—C(O)O #, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; andeach R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl;each R3a, R4a, and R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo;each R3b, R4b, and R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)1Rx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx;each RQ is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;each RV is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;each Rw is independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1. 4hydroxyalkyl, or C1-4aminoalkyl;each Rx is independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O), —C1-4alkyl;each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n-C1-4alkyl; andeach n is independently 0, 1, or 2;wherein:(a) Ring 1 comprises an intraannular amide, or(b) V comprises an amide or carbamate, or(c) V is taken together with an atom of Ring 1 to which it is attached, to form an amide or carbamate;and wherein:when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl;and wherein:when Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, and V is —OC(O)#, then RQ is not tert-butyl.In some embodiments of the compound of Formula (I), Q is RQ, and the compound is of Formula (III)or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:R is halo;Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b;Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b;Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1;V is a bond, —C1-4alkylene-, —C(O)—, —C(O)O-#, —OC(O)#—C1-4alkylene-C(O)-#, —C(O)N(RV)-#, —N(RV)C(O)-#, —OC(O)N(RV)-#, —N(RV)—C(O)O #, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; andeach R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl;each R3a, R4a, and R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo;each R3b, R4b, and R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)~Rx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx;each RQ is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;each RV is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;each Rw is independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4hydroxyalkyl, or C1-4aminoalkyl;each Rx is independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)—C1-4alkyl;each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n-C1-4alkyl; andeach n is independently 0, 1, or 2;wherein:(a) Ring 1 comprises an intraannular amide, or(b) V comprises an amide or carbamate, or(c) V is taken together with an atom of Ring 1 to which it is attached, to form an amide or carbamate;and wherein:when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.In some embodiments of the compound of Formula (I) or (II), Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b; wherein each R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; and each R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx.
[0389] In some embodiments of the compound of Formula (I) or (II), Ring 5 is C3-10 cycloalkyl optionally substituted with one or more R5a, wherein each R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 5 is C5-10 cycloalkyl optionally substituted with one or more R5a wherein each R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 5 is C5-6 cycloalkyl optionally substituted with one or more R5a, wherein each R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nR1, or oxo. In some embodiments, Ring 5 is C6 cycloalkyl optionally substituted with one or more R5a wherein each R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo.
[0390] In some embodiments of the compound of Formula (I) or (II), Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein each R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 5 is 5- to 6-membered heterocyclyl optionally substituted with one or more R5a. In some embodiments, Ring 5 is piperidinyl or piperazinyl, each of which is optionally substituted with one or more R5a. In some embodiments, Ring 5 is 10- to 12-membered heterocyclyl optionally substituted with one or more R5a. In some embodiments, Ring 5 iseach of which is optionally substituted with one or more R5a, wherein # indicates attachment to V. In some embodiments, Ring 5 iseach of which is optionally substituted with one or more R wherein # indicates attachment to V. In some embodiments, Ring 5 iseach of which is optionally substituted with one or more R5a, wherein # indicates attachment to V. In some embodiments, Ring 5 isIn some embodiments, Ring 5 isIn some embodiments, R5a is C1-4 alkyl or C(O)C1-4alkyl. In some embodiments, R5a is methyl or acetyl.In some embodiments of the compound of Formula (I) or (II), Ring 5 is 5- to 12-membered heteroaryl optionally substituted with one or more R5b, wherein each R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx. In some embodiments, Ring 5 is 5- to 6-membered heteroaryl optionally substituted with one or more R5b.In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 4 is present.In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 1 isand Q is RQ. In some embodiments, Ring 4 is present.In some embodiments of the compound of Formula (I) or (II), Ring 1 is a C4-8 cycloalkyl optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5, and wherein each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl; and each R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)~Rx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 1 is a C5-8 cycloalkyl optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5. In some embodiments, Ring 1 is a C6-8 cycloalkyl optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5. In some embodiments, Ring 1 is cyclohexyl or spiro[3.3.]heptanyl, each of which is optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5. In some embodiments, Ring 1 isRing 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5. In some embodiments, Ring 1 isRing 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5. In some embodiments, Ring 1 isRing 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5.In some embodiments, Q is Ring 5, and Ring 1, V, and Ring 5 are taken together to formIn some embodiments, Ring 4 is present.In some embodiments of the compound of Formula (I) or (II), Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular ether and no annular amine or annular amide, optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5, and wherein each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)1—C1-4alkyl; and each R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 1 is a 5- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5. In some embodiments, Ring 1 is a 6- to 8-membered heterocyclyl ring comprising no annular amine or annular amide, optionally substituted with one or more R1, Ring 5 is a 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, wherein Ring 5 comprises at least one N atom, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5.In some embodiments, Ring 1 is unsubstituted with R1. In some embodiments, Ring 1 is substituted with one or more R1. In some embodiments, Ring 1 is substituted with 1, 2, or 3 R1. In some embodiments, each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl. In some embodiments, each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, or N(Ry)C(O)C1-4haloalkyl. In some embodiments, each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, or CN.In some embodiments of the compound of Formula (I) or Formula (II), the compound is of Formula (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), or (II-g):or a stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and R, Ring 3, and Ring 4 are as defined for Formula (I). In some such embodiments, Ring 5 is 5- to 6-membered heterocyclyl optionally substituted with one or more R5a. In some such embodiments, Ring 5 is piperidinyl or piperazinyl, each of which is optionally substituted with one or more R5a. In some embodiments, Ring 4 is present.In some embodiments of Formula (I) or Formula (II), or any related formula as applicable, when Ring 5 is present, Ring 5, V, and Ring 1 are taken together to form a group of Formula (A′), (B′), (C′), (D′), (E′), (F′), (G′), (H′), or (J′):In some embodiments of the compound of Formula (I) or Formula (III), or any related formula as applicable, RQ, V, and Ring 1 are taken together to form a group of Formula (K′), (L′), (N′), or (O′):In some embodiments of the compound of Formula (I), Q is of Formula (i),and the compound is of Formula (IV),or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Ring A, X, Ring B, W, Ring C, Linker, U, Ring 2, V, Ring 1, R, Ring 3, and Ring 4 are as detailed herein for Formula (I). In some embodiments, Ring 4 is present. In some embodiments, Ring 2 is present. In some embodiments, Ring 2 and Ring 4 are each present. In some embodiments, Ring C is present. In some embodiments, Ring 2, Ring 4, and Ring C are each present.In some embodiments of the compound of Formula (I), Q is of Formula (i),and the compound is of Formula (IV),or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:R is halo;Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b;Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b;Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1;V is a bond, —C1-4alkylene-, —C(O)—, —C(O)O-#, —OC(O)#—C1-4alkylene-C(O)-#, —C(O)N(RV)-#, —N(RV)C(O)-#, —OC(O)N(RV)-#, —N(RV)—C(O)O #, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; andRing A is selected from the group consisting of each of which is optionally substituted with one or more C1-4alkyl or halo;X is a bond, —O—, —NH—, or —NHC(O)—;Ring B is selected from the group consisting of each of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RD is H or C1-4alkyl, wherein # indicates attachment to X;W is a bond, —O—, —NH—, or —NHC(O)—;Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC;Linker is a bond, —O—, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)—C1-10alkylene, C1-6alkylene-C(O)N(Ry)—C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein* indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent;L1 is a bond or C1-6 alkylene;L2 is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; andL3 is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)—C1-10alkylene, C(O)—C1-10alkylene-N(Ry), C(O)N(Ry)—C1-10alkylene, or C(O)N(Ry)—C1-10alkylene-N(Ry);U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present;Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b;each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl;each R2a, R3a, and R4a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo;each R2b, R3b, and R4b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx;each RC is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;each RL is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;each RV is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;each Rw is independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4 hydroxyalkyl, or C1-4aminoalkyl;each Rx is independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n-C1-4alkyl;each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n-C1-4alkyl; andeach n is independently 0, 1, or 2;wherein:(a) Ring 1 comprises an intraannular amide, or(b) V comprises an amide or carbamate, or(c) V is taken together with an atom of Ring 1 or Ring 2 to which it is attached, to form an amide or carbamate;and wherein:when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl.In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring A is selected from the group consisting ofeach of which is optionally substituted with C1-4alkyl or halo. In some embodiments, Ring A isoptionally substituted with C1-4alkyl or halo. In some embodiments, Ring A isIn some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), X is a bond, —O—, —NH—, or —NHC(O)—. In some embodiments, X is a bond or —NH—.In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring B is selected from the group consisting ofeach of which is optionally substituted with one or more halo or OH, wherein RD is H or C1-4alkyl. In some embodiments, Ring B is selected from the group consisting ofeach of which is optionally substituted with one or more halo or OH, wherein RD is H or C1-4alkyl, # indicates attachment to X, and ## indicates attachment to W. In some embodiments, Ring B isoptionally substituted with one or more halo or OH. In some embodiments, Ring B isIn some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), W is a bond, —O—, —NH—, or —NHC(O)—. In some embodiments, W is a bond or —O—.In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring C is absent.In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-c), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring C is present and is 4- to 12-membered heterocyclyl optionally substituted with one or more RC, wherein each RC is independently halo, OH, C1-4alkyl, or C1-4haloalkyl. In some embodiments, Ring C is 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more RC. In some embodiments, Ring C is 5- to 6-membered heterocyclyl optionally substituted with one or more RC. In some embodiments, Ring C isoptionally substituted with one or more RC, wherein Y and Z are independently CH or N. In some embodiments, Ring C is piperidinyl or piperazinyl, each of which is optionally substituted with one or more RC. In some embodiments, Ring C is piperidinyl optionally substituted with one or more RC. In some embodiments, Ring C is piperazinyl optionally substituted with one or more RC. In some embodiments, Ring C iseach of which is optionally substituted with one or more RC. In some embodiments, Ring C iseach of which is optionally substituted with one or more RC, wherein # indicates attachment to W and ## indicates attachment to Linker. In some embodiments, Ring C iswherein # indicates attachment to W and ## indicates attachment to Linker.In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Linker is a bond, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)—C1-10alkylene, C1-6alkylene-C(O)N(Ry)—C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein * indicates attachment to Ring C when Ring C is present, or attachment to W when Ring C is absent; and ** indicates attachment to U when Ring 2 is present, or attachment to V when Ring 2 is absent; L1 is a bond or C1-6 alkylene; L2 is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL, wherein each RL is independently halo, OH, C1-4alkyl, or C1-4haloalkyl; and L3 is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)—C1-10alkylene, C(O)—C1-10alkylene-N(Ry), C(O)N(Ry)—C1-10alkylene, or C(O)N(Ry)—C1-10alkylene-N(Ry).In some embodiments of the compound of Formula (I′), (I), or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Linker is a bond, —O—, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)—C1-10alkylene, C1-6alkylene-C(O)N(Ry)—C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein * indicates attachment to Ring C when Ring C is present, or attachment to W when Ring C is absent; and ** indicates attachment to U when Ring 2 is present, or attachment to V when Ring 2 is absent; L1 is a bond or C1-6 alkylene; L2 is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL, wherein each RL is independently halo, OH, C1-4alkyl, or C1-4haloalkyl; and L3 is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)—C1-10alkylene, C(O)—C1-10alkylene-N(Ry), C(O)N(Ry)—C1-10alkylene, or C(O)N(Ry)—C1-10alkylene-N(Ry).In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Linker is a bond, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)—C1-10alkylene, C1-6alkylene-C(O)N(Ry)—C1-10alkylene-N(Ry). In some embodiments of the compound of Formula (I) or (IV), Linker is a bond, C1-10alkylene, or C(O)C1-10alkylene.In some embodiments of the compound of Formula (I) or (IV), Linker is a bond, C1-10alkylene, C(O)—C1-10alkylene, C1-6alkylene-C(O)—C1-10alkylene, C0-6alkylene-C(O)N(Ry)—C1-10alkylene, or is of the formula *-L1-L2-L3-**, wherein L1 is a bond or C1-6 alkylene, L2 is a piperidinyl ring or piperazinyl ring, and L3 is C1-10 alkylene. In some embodiments, Linker is a bond, C1-2alkylene, C(O)—C1-2alkylene, or C1-2alkylene-C(O)N(Ry)—C1-10alkylene.In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-c), or (IV-d), Ring 2 is absent.In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 2 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b, wherein each R2a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; and each R2b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx; and U is a bond. In some embodiments, the 4- to 12-membered heterocyclyl optionally substituted with one or more R2a is a nitrogen-containing heterocyclyl.In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 2 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b, wherein each R2a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo; and each R2b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)~Rx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx; and U is C(O). In some embodiments, the 4- to 12-membered heterocyclyl optionally substituted with one or more R2a is a nitrogen-containing heterocyclyl.In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 2 is C3-10 cycloalkyl optionally substituted with one or more R5a, wherein each R2a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 2 is C5-10 cycloalkyl optionally substituted with one or more R5a. In some embodiments, Ring 2 is C5-6 cycloalkyl optionally substituted with one or more R5a. In some embodiments, Ring 2 is C6 cycloalkyl optionally substituted with one or more R5a.In some embodiments, Ring 2 iseach of which is optionally substituted with one or more R2a, wherein # indicates attachment to V.In some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, wherein each R2a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, Ring 2 is 5- to 6-membered heterocyclyl optionally substituted with one or more R2a. In some embodiments, Ring 2 is 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a. In some embodiments, Ring 2 is 5- to 6-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a. In some embodiments, Ring 2 is piperidinyl or piperazinyl, each of which is optionally substituted with one or more R2a. In some embodiments, Ring 2 is 10- to 12-membered heterocyclyl optionally substituted with one or more R2a. In some embodiments, Ring 2 iseach of which is optionally substituted with one or more R2a, wherein # indicates attachment to V. In some embodiments, Ring 2 iseach of which is optionally substituted with one or more R2a, wherein # indicates attachment to V. In some embodiments, Ring 2 isIn some embodiments, Ring 2 isIn some embodiments, Ring 2 isIn some embodiments, Ring 2 isIn some embodiments of the compound of Formula (I) or (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 2 is 5- to 12-membered heteroaryl optionally substituted with one or more R5b, wherein each R2b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)~Rx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx. In some embodiments, Ring 2 is 5- to 6-membered heteroaryl optionally substituted with one or more R5b.In some embodiments of the compound of Formula (I′), or any related formula such as (I), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), each R2a, R3a, R4a, and R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)aN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo. In some embodiments, each R2a, R3a, R4a, and R5a is C(O)Rw. In some embodiments, each R3a is C(O)Rw.In some embodiments of the compound of Formula (I′), or any related formula such as (I), (IV), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), (I-ag), (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), each R2b, R3b, R4b, and R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)~Rx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx. In some embodiments, each R2b, R3b, R4b, and R5b is independently C(O)Rw or C1-4hydroxyalkyl. In some embodiments, each R2b, R3b, R4b, and R5b is independently C(O)Rw. In some embodiments, each R2b, R3b, R4b, and R5b is independently C1-4hydroxyalkyl. In some embodiments, each R3b is independently C(O)Rw or C1-4hydroxyalkyl. In some embodiments, each R3b is independently C(O)Rw. In some embodiments, each R3b is independently C1-4hydroxyalkyl. In some embodiments, each R3b isIn some embodiments, each Rw is independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4hydroxyalkyl, or C1-4aminoalkyl. In some embodiments, each Rw is independently 3- to 10-membered cycloalkyl. In some embodiments, each Rw is independently phenyl optionally substituted with halo. In some embodiments, each Rw is phenyl optionally substituted with fluoro or chloro. In some embodiments, each Rw is phenyl optionally substituted with fluoro. In some embodiments, each Rw is phenyl optionally substituted with chloro. In some embodiments, each Rw is independently 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4hydroxyalkyl, or C1-4aminoalkyl. In some embodiments, each Rw is 4- to 12-membered heterocyclyl optionally substituted with hydroxyl. In some embodiments, each Rw is 4- to 12-membered heterocyclyl optionally substituted with C1-4hydroxyalkyl. In some embodiments, each Rw is 4- to 12-membered heterocyclyl optionally substituted with C1-4aminoalkyl. In some embodiments, Rw isIn some embodiments, each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n-C1-4alkyl. In some embodiments, each Ry and Rz is independently 3- to 10-membered cycloalkyl. In some embodiments, one of Ry and Rz is hydrogen and the other is 3- to 10-membered cycloalkyl. In some embodiments, one of Ry and Rz is hydrogen and the other is cyclopropyl.In some embodiments, each RV is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl. In some embodiments, each RV is independently H or C1-4alkyl. In some embodiments, each RV is independently H or C1-2alkyl. In some embodiments, each RV is independently H or methyl. In some embodiments, each RV is independently H or ethyl. In some embodiments, each RV is H. In some embodiments, each RV is methyl. In some embodiments, each RV is ethyl.In some embodiments of Formula (IV), Ring C, U, and Ring 2 are present, and the compound is of Formula (IV-a). In some embodiments of Formula (IV), U and Ring 2 are present, and Ring C is absent, and the compound is of Formula (IV-a). In some embodiments, Ring C is present, and U and Ring 2 are absent, and the compound is of Formula (IV-c). In some embodiments, Ring C, U, and Ring 2 are absent, and the compound is of Formula (IV-d). In some embodiments, the compound of Formula (I) or (IV) is of Formula (IV-a), (IV-a), (IV-c), or (IV-d):wherein Ring A, X, Ring B, W, Ring C, Linker, U, Ring 2, V, Ring 1, R, Ring 3, and Ring 4 are as described herein for Formula (I).In some embodiments of Formula (I), Formula (IV), or any related formula such as Formula (IV-a), (IV-a), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), when Ring 2 is present, Ring 2, V, and Ring 1 are taken together to form a group of Formula (A), (B), (C), (D), (E), (F), (G), (H), or (J):In some such embodiments, Ring 2, V, and Ring 1 are taken together to form a group of Formula (C), (D), or (E). In some such embodiments, when Ring 2 is present, Ring 2, V, and Ring 1 are taken together to form a group of Formula (K), (L), (M), or (N):In some such embodiments, when Ring 2 is present, Ring 2, V, and Ring 1 are taken together to form a group of Formula (O), (P), (Q), or (R), or a stereoisomer thereof:In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 1 is a saturated 4- to 8-membered heterocyclyl comprising an annular amide, optionally substituted with one or more R1, and V is a bond or C1-4 alkylene. In some embodiments, Ring 1 is a saturated 5- to 6-membered heterocyclyl comprising an annular amide, optionally substituted with one or more R1, and V is a bond or C1-4 alkylene. In some embodiments, Ring 1 isoptionally substituted with one or more R1, wherein # indicates attachment to V, which is a bond or C1-4 alkylene. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, and V is a bond or C1-4 alkylene. In some embodiments, Ring 1 isand V is a bond or C1-4 alkylene. In some embodiments, Ring 1 isand V is a bond or C1-4 alkylene.In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (IV-a), (IV-a), (IV-c), or (IV-d), Ring 1 is a saturated 4- to 8-membered heterocyclyl comprising at least one annular amine, optionally substituted with one or more R1, and V is —C(O)— or —C1-4alkylene-C(O)—. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 5- to 8-membered heterocyclyl comprising at least one annular amine, optionally substituted with one or more R1, and V is —C(O)— or —C1-4alkylene-C(O)—. In some embodiments of the compound of Formula (I), Ring 1 is a saturated 6- to 8-membered heterocyclyl comprising at least one annular amine, optionally substituted with one or more R1, and V is —C(O)— or —C1-4alkylene-C(O)—. In some embodiments, Ring 1 is piperidinyl or 2-azaspiro[3.3]heptanyl, each of which is optionally substituted with one or more R1, and V is —C(O)— or —C1-4alkylene-C(O)—. In some embodiments, Ring 1 iswherein # indicates attachment to V, each of which is optionally substituted with one or more R1, and V is —C(O)— or —C1-4alkylene-C(O)—. In some embodiments, Ring 1 iswherein # indicates attachment to V, each of which is optionally substituted with one or more R1, and V is —C(O)— or —C1-4alkylene-C(O)—. In some embodiments, Ring 1 isand V is —C(O)— or —C1-4alkylene-C(O)—. In some embodiments, Ring 1 isand V is —C(O)— or —C1-4alkylene-C(O)—. In some embodiments, Ring 1 isand V is —C(O)— or —C1-4alkylene-C(O)—.In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (IV-a), (IV-a), (IV-c), or (IV-d), Ring 1 is a C4-8 cycloalkyl optionally substituted with one or more R1, and V is —C(O)N(RV)-#, —N(RV)C(O)-#, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#.In some embodiments of the compound of Formula (I), (IV), or any related formula such as (IV-a) or (IV-a), Ring 1 is a C4-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is a C5-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is a C6-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is cyclohexyl or spiro[3.3.]heptanyl, each of which is optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 isRing 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 isRing 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 isRing 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2.In some embodiments of the compound of Formula (I), (IV), or any related formula such as (IV-a) or (IV-a), Ring 1 is a C4-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is a C5-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is a C6-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is cyclohexyl or spiro[3.3.]heptanyl, each of which is optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 iseach of which is optionally substituted with one or more R1, Ring 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 isRing 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 isRing 2 is a 4- to 12-membered nitrogen-containing heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2. In some embodiments, Ring 1 is a C4-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a C4-8 cycloalkyl optionally substituted with one or more R2a, and V is —C(O)N(RV)-#, wherein # indicates the point of attachment to Ring 1. In some embodiments, Ring 1 is a C5-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a C5-8 cycloalkyl optionally substituted with one or more Ra and V is —C(O)N(RV)-#, wherein # indicates the point of attachment to Ring 1. In some embodiments, Ring 1 is a C6-8 cycloalkyl optionally substituted with one or more R1, Ring 2 is a C6-8 cycloalkyl optionally substituted with one or more R2a, and V is —C(O)N(RV)-#, wherein # indicates the point of attachment to Ring 1. In some embodiments, Ring 1 is a cyclohexyl optionally substituted with one or more R1, Ring 2 is a cyclohexyl optionally substituted with one or more R2a, and V is —C(O)N(RV)-#, wherein # indicates the point of attachment to Ring 1.In some embodiments of the compound of Formula (I) or Formula (IV), Ring 2 is present and the compound is of Formula (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l):In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is 3- to 6-membered cycloalkyl optionally substituted with one or more R3a, 4- to 6-membered heterocyclyl optionally substituted with one or more R3a, phenyl optionally substituted with one or more R3b, or 5- to 6-membered heteroaryl optionally substituted with one or more R3b, wherein each R3a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)aN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo, and each R3b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)~Rx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx. In some embodiments, each R3a is independently halo, methyl, trifluoromethyl, OH, OCH3, acetyl, CN, or oxo. In some embodiments, each R3a is oxo. In some embodiments, each R3b is independently halo, methyl, trifluoromethyl, OH, OCH3, acetyl, or CN.In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is 3- to 6-membered cycloalkyl optionally substituted with one or more R3a.In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is 4- to 6-membered heterocyclyl optionally substituted with one or more R3a. In some embodiments of the compound of Formula (I), Ring 3 is 4- to 6-membered nitrogen-containing heterocyclyl optionally substituted with one or more R3a. In some embodiments, Ring 3 is pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl. In some embodiments, Ring 3 iseach of which is optionally substituted with one or more R3a. In some embodiments, Ring 3 iseach of which is optionally substituted with one or more R3a, wherein # indicates attachment to the pyrimidine ring of Formula (I), and ## indicates attachment to Ring 4, when present. In some embodiments, Ring 3 iseach of which is optionally substituted with one or more R3a. In some embodiments, Ring 3 iswherein # indicates attachment to the pyrimidine ring of Formula (I), and ## indicates attachment to Ring 4, when present.In some embodiments of the compound of Formula (I), (II), (III), or (IV), or a related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is phenyl optionally substituted with one or more R3b. In some embodiments, Ring 3 isoptionally substituted with one or more R3b. In some embodiments, Ring 3 isIn some embodiments, Ring 3 isIn some embodiments, each R3b is independently halo, methyl, trifluoromethyl, OH, OCH3, acetyl, or CN. In some embodiments, each R3b is independently halo, methyl, or OCH3.In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (J-d), (I-e), (I-f), (J-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is 5- to 6-membered heteroaryl optionally substituted with one or more R3b. In some embodiments, Ring 3 is 5- to 6-membered nitrogen-containing heteroaryl optionally substituted with one or more R3b. In some embodiments, Ring 3 is 6-membered heteroaryl optionally substituted with one or more R3b. In some embodiments, Ring 3 is 5-membered heteroaryl optionally substituted with one or more R3b. In some embodiments, Ring 3 is pyrazolyl optionally substituted with one or more R3b. In some embodiments, Ring 3 iseach of which is optionally substituted with one or more R3b. In some embodiments, Ring 3 iseach of which is optionally substituted with one or more R3b, wherein # indicates attachment to the pyrimidine ring of Formula (I), and ## indicates attachment to Ring 4, when present. In some embodiments, Ring 3 iswherein # indicates attachment to the pyrimidine ring of Formula (I), and ## indicates attachment to Ring 4, when present. In some embodiments, Ring 3 is 6-membered heteroaryl optionally substituted with one or more R3b. In some embodiments, Ring 3 is pyridinyl, pyrimidinyl, or pyrazinyl optionally substituted with one or more R3b.In some embodiments, Ring 3 iseach of which is optionally substituted with one or more R3b, wherein # indicates attachment to the pyrimidine ring of Formula (I), and ## indicates attachment to Ring 4, when present.In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is other than 5-membered heteroaryl, and Ring 4 is absent. In some such embodiments, Ring 3 is 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 6-membered heteroaryl optionally substituted with one or more R3b, and Ring 4 is absent. In some such embodiments, Ring 3 is 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; or phenyl optionally substituted with one or more R3b; and Ring 4 is absent.In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 4 is present. In some embodiments, Ring 4 is present and is unsubstituted. In some embodiments, Ring 4 is present and is unsubstituted or substituted with halo. In some embodiments, Ring 4 is phenyl substituted with halo. In some embodiments, Ring 4 is phenyl substituted with fluoro.In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 4 is present and is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b, wherein each R4a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)aN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo, and each R4b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)~Rx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx, wherein when Ring 3 is 5-membered heteroaryl, Ring 4 is not cycloalkyl or tetrahydropyranyl. In some embodiments, each R4a is independently halo, methyl, trifluoromethyl, OH, OCH3, acetyl, CN, or oxo. In some embodiments, each R4a is methyl or acetyl. In some embodiments, each R4b is independently halo, methyl, trifluoromethyl, OH, OCH3, acetyl, or CN.In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 4 is 3- to 6-membered cycloalkyl optionally substituted with one or more R4a and Ring 3 is not 5-membered heteroaryl. In some embodiments, Ring 4 is 4- to 6-membered cycloalkyl optionally substituted with one or more R4a, and Ring 3 is not 5-membered heteroaryl. In some embodiments, Ring 4 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl optionally substituted with one or more R4a, and Ring 3 is not 5-membered heteroaryl. In some embodiments, Ring 4 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, and Ring e is not 5-membered heteroaryl. In some embodiments, Ring 4 is cyclobutyl, cyclopentyl, or cyclohexyl, and Ring 3 is not 5-membered heteroaryl.In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as ((I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 4 is 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, wherein when Ring 3 is 5-membered heteroaryl, Ring 4 is not tetrahydropyranyl. In some embodiments, Ring 4 is 4- to 6-membered nitrogen-containing heterocyclyl optionally substituted with one or more R4a. In some embodiments, Ring 4 is 5- to 6-membered nitrogen-containing heterocyclyl optionally substituted with one or more R4a. In some embodiments, Ring 4 is pyrrolidinyl, piperidinyl, or piperazinyl, each of which is optionally substituted with one or more R4a. In some embodiments, Ring 4 is pyrrolidinyl or piperidinyl, each of which is optionally substituted with one or more R4a. In some embodiments, Ring 4 iseach of which is optionally substituted with one or more R4a. In some embodiments, Ring 4 isIn some embodiments, each R4a is independently halo, methyl, trifluoromethyl, OH, OCH3, acetyl, CN, or oxo. In some embodiments, each R4a is methyl or acetyl.In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 4 is phenyl optionally substituted with one or more R4b. In some embodiments, Ring 4 isIn some embodiments, each R4a is independently halo, methyl, trifluoromethyl, OH, OCH3, acetyl, or CN. In some embodiments, each R4a is halo, methyl, or OCH3.In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 4 is 5- to 6-membered heteroaryl optionally substituted with one or more R4b. In some embodiments, Ring 4 is 5- to 6-membered nitrogen-containing heteroaryl optionally substituted with one or more R4b. In some embodiments, Ring 4 is 6-membered heteroaryl optionally substituted with one or more R4b. In some embodiments, Ring 4 is pyridinyl or pyrazinyl, each of which is optionally substituted with one or more R4b. In some embodiments, Ring 4 iseach of which is optionally substituted with one or more R4b. In some embodiments, Ring 4 iseach of which is optionally substituted with one or more R4b. In some embodiments, Ring 4 isIn some embodiments, Ring 4 isoptionally substituted with one or more R4b.In some embodiments, Ring 4 iseach of which is optionally substituted with one or more R4a.In some embodiments, Ring 4 iseach of which is optionally substituted with one or more R4a.In some embodiments of the compound of Formula (I), (II), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is 3- to 6-membered cycloalkyl optionally substituted with one or more R3a, 4- to 6-membered heterocyclyl optionally substituted with one or more R3a, phenyl optionally substituted with one or more R3b, or 6-membered heteroaryl optionally substituted with one or more R3b; and Ring 4 is absent. In some embodiments of the compound of Formula (I), Ring 3 is 3- to 6-membered cycloalkyl optionally substituted with one or more R3a, 4- to 6-membered heterocyclyl optionally substituted with one or more R3a, or phenyl optionally substituted with one or more R3b; and Ring 4 is absent.In some embodiments of the compound of Formula (I), (TT), (III), (IV), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (II-a), (II-b), (II-c), (II-d), (II-e), (II-f), (II-g), (IV-a), (IV-b), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring 3 is 5-membered heteroaryl, and Ring 4 is present and is not cycloalkyl or tetrahydropyranyl. In some embodiments of the compound of Formula (I), Ring 3 is 5-membered heteroaryl, and Ring 4 is present and is 4- to 6-membered nitrogen-containing heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, or 5- to 6-membered heteroaryl optionally substituted with one or more R4b. In some embodiments of the compound of Formula (I), Ring 3 is 5-membered heteroaryl, and Ring 4 is present and is phenyl optionally substituted with one or more R4b, or 5- to 6-membered heteroaryl optionally substituted with one or more R4b.In some embodiments, Ring 3 is phenyl, and Ring 4 is present and is 4- to 6-membered nitrogen-containing heterocyclyl optionally substituted with one or more R4a phenyl optionally substituted with one or more R4b, or 5- to 6-membered heteroaryl optionally substituted with one or more R4b. In some embodiments, Ring 3 is phenyl and Ring 4 is present and is 4- to 6-membered nitrogen-containing heterocyclyl optionally substituted with one or more R4a. In some embodiments, Ring 3 is phenyl and Ring 4 is present and isIn some embodiments of the compound of Formula (I), or any related formula such as (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), Ring 4 is absent and Q is of Formula (i). In some embodiments, Ring 4 is present and Q is of Formula (i).In some embodiments, Ring 4 is absent. In some embodiments, Ring 4 is present.In some embodiments of the compound of Formula (I), or any related formula such as Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-y), (IV-a), (IV-a), (IV-c), (IV-d), (IV-e), (IV-f), (IV-g), (IV-h), (IV-j), (IV-k), or (IV-l), Ring A, X, Ring B, W, and C together are:wherein eachis optionally substituted with one or more RC, and wherein Y and Z are independently CH or N. In some embodiments, Ring A, X, Rin B, W, and C together are:wherein eachis optionally substituted with one or more RC, and wherein Y and Z are independently CH or N. In some embodiments, Ring A, X, Ring B, W, and C together are:wherein eachis optionally substituted with one or more RC, and wherein Y and Z are independently CH or N. In some embodiments, Ring A, X, Ring B, W, and C together are:wherein eachis optionally substituted with one or more RC, and wherein Y and Z are independently CH or N.In some embodiments, Ring A, X, Ring B, W, and C together are:whereinis optionally substituted with R2b, wherein eachis optionally substituted with one or more RC, and wherein Y and Z are independently CH or N.In some embodiments, when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl; and when Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, Q is RQ, and V is —OC(O)#, then RQ is not tert-butyl. In some embodiments, when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl. In some embodiments, when Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, Q is RQ, and V is —OC(O)#, then RQ is not tert-butyl.It is to be understood that all embodiments of Formula (I) and sub-formulas thereof, also apply to Formulas (II), (III), and (IV), including all sub-formulas, and variations thereof, as applicable. Further, the present disclosure contemplates combinations of features as disclosed herein, as if each were individually listed. Exemplary combinations of features are provided herein but are not to be construed as limiting.It is to be understood that all embodiments of Formula (I) and sub-formulas thereof, also apply to Formulas (I′), (II), (III), and (IV), including all sub-formulas, and variations thereof, as applicable. Further, the present disclosure contemplates combinations of features as disclosed herein, as if each were individually listed. Exemplary combinations of features are provided herein but are not to be construed as limiting.Representative compounds are listed in Table 1 and Table 2.In some embodiments of a compound of Formula (I′) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from Table 1 or Table 2. In some embodiments of a compound of Formula (I′) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from Table 1. In some embodiments of a compound of Formula (I′) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from Table 2.In some embodiments of a compound of Formula (I′) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-43 and 91 of Table 1, and compounds 44-90 of Table 2. In some embodiments of a compound of Formula (I′) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-43 and 91-274 of Table 1, and compounds 44-90 and 275-605 of Table 2. In some embodiments of a compound of Formula (I′) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-43, 91-274, and 606-631 of Table 1, and compounds 44-90, 275-605, and 632-705 of Table 2. In some embodiments of a compound of Formula (I′) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-43 and 91 of Table 1. In some embodiments of a compound of Formula (I′) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-43 and 91-274 of Table 1. In some embodiments of a compound of Formula (I′) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 1-43, 91-274, and 606-631 of Table 1. In some embodiments of a compound of Formula (I′) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 44-90 of Table 2. In some embodiments of a compound of Formula (I′) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 44-90 and 275-605 of Table 2. In some embodiments of a compound of Formula (I′) or (I), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from compounds 44-90, 275-605, and 632-705 of Table 2.TABLE 1Representative Compounds of Formula (I′), (I), (II), and (III)Cmpd.No.StructureName14-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)cyclohexane-1- carboxamide2(4-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-1- yl)(piperidin-4- yl)methanone3(4-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-1-yl)(1- methylpiperidin-4- yl)methanone41-(4-(4-((4-([1,1′- biphenyl]-3-yl)-5- choropyrimidin-2- yl)amino)piperidine-1- carbonyl)piperidin-1- yl)ethan-1-one51-(4-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-1-yl)-2- (piperidin-4-yl)ethan-1-one61-(4-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-1-yl)-2- (1-acetylpiperidin-4- yl)ethan-1-one71-(4-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-1-yl)-3- (piperidin-4-yl)propan-1- one81-(4-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-1-yl)-3- (1-acetylpiperidin-4- yl)propan-1-one91-(4-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-1-yl)-2- (1-methylpiperidin-4- yl)ethan-1-one101-(4-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-1-yl)-3- (1-methylpiperidin-4- yl)propan-1-one11(4-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-1-yl)(3- azaspiro[5.5]undecan-9- yl)methanone12(4-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-1-yl)(3- methyl-3- azaspiro[5.5]undecan-9- yl)methanone131-(9-(4-((4-([′,1′- biphenyl]-3-yl)-5- chloropyrimidin-2- yl)amino)piperidine-1- carbonyl)-3- azaspiro[5.5]undecan-3- yl)ethan-1-one145-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)-1- methylpiperidin-2-one154-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-2-one164-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)-1- methylpiperidin-2-one175-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-2-one18(S)-1-(3-((4-([1,1′- biphenyl]-3-yl)-5- chloropyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one19trans-4-((4-([1,1′- biphenyl]-3-yl)-5- chloropyrimidin-2- yl)amino)cyclohexane-1- carboxamide201-((3S)-3-((5-chloro-4-(3- phenylpyrrolidin-1- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one211-(3-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one223-((4-([1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)cyclohexane-1- carboxamide231-(4-((4-[(1,1′-biphenyl]-3- yl)-5-chloropyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one241-(4-((5-chloro-4- (piperidin-1-yl)pyrimidin- 2-yl)amino)piperidin-1- yl)ethan-1-one25cis-4-((5-chloro-4-(4- fluorophenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide261-(3-((5-chloro-4-(4- fluorophenyl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one271-(4-((5-chloro-4-(4- fluorophenyl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one28trans-3-((5-chloro-4-(4- fluorophenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide291-((3S)-3-((5-chloro-4-(3- (pyridin-2-yl)pyrrolidin-1- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one301-(4-((5-chloro-4-(1- phenylpyrrolidin-3- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one31cis-N-(4-((4-([1,1′- biphenyl]-3-yl)-5- chloropyrimidin-2- yl)amino)cyclohexyl) acetamide32trans-N-(4-((4-([1,1′- biphenyl]-3-yl)-5- chloropyrimidin-2- yl)amino)cyclohexyl) acetamide33cis-N-(3-((4-([1,1′- biphenyl]-3-yl)-5- chloropyrimidin-2- yl)amino)cyclohexyl) acetamide34trans-N-(3-((4-([1,1′- biphenyl]-3-yl)-5- chloropyrimidin-2- yl)amino)cyclohexyl) acetamide351-((3S)-3-((5-chloro-4-(3- phenylpiperidin-1-yl) pyrimidin-2-yl) amino)piperidin-1-yl) ethan-1-one36cis-3-((5-fluoro-4-(3- (pyrrolidin-1- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide37(S)-1-(3-((5-chloro-4-(3- (piperidin-1- yl)phenyl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one38cis-3-((4-(3- cyclobutylphenyl)-5- fluoropyrimidin-2- yl)amino)cyclohexane-1- carboxamide39(S)-1-(3-((5-chloro-4-(3- cyclohexylphenyl) pyrimidin-2-yl)amino) piperidin-1-yl)ethan-1-one403-[[5-fluoro-4-[3-(2-oxo-1- pyridyl)phenyl]pyrimidin- 2-yl]amino]cyclohexane- carboxamide41cis-3-((5-fluoro-4-(1-(4- fluorophenyl)-6-oxo-1,6- dihydropyridin-3- yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide42cis-3-((5-fluoro-4-(1-(4- fluorophenyl)-1H-pyrazol- 3-yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide43cis-3-((5-fluoro-4-(1-(4- fluorophenyl)-1H-pyrazol- 4-yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide91cis-3-((5-fluoro-4-(1-(4- fluorophenyl)piperidin-3- yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide92trans-(1r,4r)-4-((5-chloro- 4-(3-(6-oxo-1,6- dihydropyridin-2- yl)phenyl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide93cis-N-((1s,4s)-4-((5-chloro- 4-(3-(2-oxopyridin-1(2H)- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide94cis-3-((5-chloro-4-(3-(2- oxopyridin-1(2H)- yl)phenyl)pyrimidin-2- yl)amino)-N- methylcyclobutane-1- carboxamide95trans-(1r,4r)-4-((5-chloro- 4-(1-(4-fluorophenyl)-6- oxo-1,6-dihydropyridin-3- yl)pyrimidin-2-yl)amino)- N-methylcyclohexane-1- carboxamide96trans-N-((1r,4r)-4-((5- chloro-4-(1-cyclopropyl-6- oxo-1,6-dihydropyridin-3- yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide97cis-3-((5-chloro-4-(1- cyclopropyl-1H-pyrazol-4- yl)pyrimidin-2-yl)amino)- N-methylcyclobutane-1- carboxamide981-(4-((5-chloro-4-(1- cyclopropyl-1H-pyrazol-4- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one99cis-N-((1s,4s)-4-((5-chloro- 4-(1-cyclopropyl-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide100trans-N-(4-((5-chloro-4-(1- (cyclopropanecarbonyl) piperidin-3-yl)pyrimidin- 2-yl)amino) cyclohexyl)acetamide101trans-(1r,4r)-4-((5-chloro- 4-(4′-fluoro-[1,1′- biphenyl]-3-yl)pyrimidin- 2-yl)amino)-N- methylcyclohexane-1- carboxamide102trans-N-((1r,4r)-4-((5- chloro-4-(3-(2-oxopyridin- 1(2H)- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide103trans-(1r,4r)-4-((5-chloro- 4-(3-(2-oxopyridin-1(2H)- yl)phenyl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide104cis-(1s,4s)-4-((5-chloro-4- (3-(2-oxopyridin-1(2H)- yl)phenyl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide1051-(4-((5-chloro-4-(2-(4- fluorophenyl)pyridin-4- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one106trans-(1r,4r)-4-((5-chloro- 4-(1-cyclopropyl-6-oxo- 1,6-dihydropyridin-3- yl)pyrimidin-2-yl)amino)- N-methylcyclohexane-1- carboxamide107cis-(1s,4s)-4-((5-chloro-4- (1-cyclopropyl-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide108cis-(1s,4s)-4-((5-chloro-4- (1-cyclohexyl-1H-pyrazol- 4-yl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide1091-(4-((5-chloro-4-(1- cyclohexyl-1H-pyrazol-3- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one1105-(4-(2-((1-acetylpiperidin- 4-yl)amino)-5- chloropyrimidin-4-yl)-1H- pyrazol-1-yl)pyridin- 2(1H)-one1113-(4-(2-((1-acetylpiperidin- 4-yl)amino)-5- chloropyrimidin-4-yl)-1H- pyrazol-1-yl)pyridin- 2(1H)-one112cis-3-((5-fluoro-4-(3-(6- oxo-1,6-dihydropyridin-2- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide113cis-3-((4-(1-cyclohexyl- 1H-pyrazol-3-yl)-5- fluoropyrimidin-2- yl)amino)cyclohexane-1- carboxamide1141-(4-((5-chloro-4-(6-(4- fluorophenyl)pyridin-2- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one115cis-3-((5-chloro-4-(6-(4- fluorophenyl)pyridin-2- yl)pyrimidin-2-yl)amino)- N-methylcyclobutane-1- carboxamide116trans-N-((1r,4r)-4-((5- chloro-4-(1-cyclopropyl- 1H-pyraazol-4- yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide117trans-(1r,4r)-4-((5-chloro- 4-(1-cyclopropyl-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide118trans-(1r,4r)-4-((5-chloro- 4-(1-cyclohexyl-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide119trans-(1r,3r)-3-((5-chloro- 4-(1-(6-oxo-1,6- dihydropyridin-3-yl)-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)-N- methylcyclobutane-1- carboxamide1204-(4-(2-((1-acetylpiperidin- 4-yl)amino)-5- chloropyrimidin-4-yl)-1H- pyrazol-1-yl)pyridin- 2(1H)-one121trans-N-((1r,4r)-4-((5- chloro-4-(1-(4- fluorophenyl)-1H-pyrazol- 4-yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide122cis-3-((5-chloro-4-(1-(4- fluorophenyl)-1H-pyrazol- 4-yl)pyrimidin-2- yl)amino)-N- methylcyclobutane-1- carboxamide123trans-(1r,3r)-3-((5-chloro- 4-(1-(4-fluorophenyl)-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)-N- methylcyclobutane-1- carboxamide124trans-N-(4-((5-chloro-4-(1- (4-fluorobenzoyl)piperidin- 3-yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide1251-(4-((5-chloro-4-(1-(4- fluorobenzoyl)piperidin-3- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one126trans-N-(4-((5-chloro-4-(1- (4- fluorobenzoyl)pyrrolidin- 3-yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide1271-(4-((5-chloro-4-(1-(4- fluorobenzoyl)pyrrolidin- 3-yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one128(S)-1-(3-((5-chloro-4-(4′- fluoro-[1,1′-biphenyl]-3- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one129(S)-1-(3-(2-((1- acetylpiperidin-3- yl)amino)-5- chloropyrimidin-4- yl)phenyl)pyridin-2(1H)- one130cis-N-((1s,4s)-4-((5-chloro- 4-(6-(4- fluorophenyl)pyridin-2- yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide131cis-(1s,4s)-4-((5-chloro-4- (6-(4-fluorophenyl)pyridin- 2-yl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide1321-(4-((5-chloro-4-(5- cyclopropyl-1H-pyrazol-3- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one133trans-(1r,3r)-3-((5-chloro- 4-(1-(2-oxo-1,2- dihydropyridin-4-yl)-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)-N- methylcyclobutane-1- carboxamide134trans-(1r,4r)-4-((5-chloro- 4-(1-(4-fluorophenyl)-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide135cis-3-((5-chloro-4-(1-(4- fluorobenzoyl)pyrrolidin- 3-yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide136cis-3-((5-chloro-4-(3-(2- oxopyridin-1(2H)- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide1373-(3-(2-((1-acetylpiperidin- 4-yl)amino)-5- chloropyrimidin-4- yl)phenyl)pyridin-2(1H)- one138cis-(1s,4s)-4-((5-chloro-4- (3-(2-oxo-1,2- dihydropyridin-3- yl)phenyl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide139trans-(1r,3r)-3-((5-chloro- 4-(3-(2-oxo-1,2- dihydropyridin-3- yl)phenyl)pyrimidin-2- yl)amino)-N- methylcyclobutane-1- carboxamide140trans-(1r,3r)-3-((5-chloro- 4-(6-(4- fluorophenyl)pyridin-2- yl)pyrimidin-2-yl)amino)- N-methylcyclobutane-1- carboxamide141(S)-1-(3-((5-chloro-4-(2- (4-fluorophenyl)pyridin-4- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one142trans-N-((1r,4r)-4-((5- chloro-4-(2-(4- fluorophenyl)pyridin-4- yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide143(S)-5-(2-((1- acetylpiperidin-3- yl)amino)-5- chloropyrimidin-4-yl)-1- (4-fluorophenyl)pyridin- 2(1H)-one144trans-(1r,4r)-4-((5-chloro- 4-(5-cyclopropyl-1H- pyrazol-3-yl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide145trans-N-((1r,4r)-4-((5- chloro-4-(1-(6-oxo-1,6- dihydropyridin-3-yl)-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide146trans-(1r,4r)-4-((5-chloro- 4-(1-(6-oxo-1,6- dihydropyridin-3-yl)-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide147trans-N-((1r,4r)-4-((5- chloro-4-(1-(2-oxo-1,2- dihydropyridin-4-yl)-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide148cis-(1s,4s)-4-((5-chloro-4- (1-(2-oxo-1,2- dihydropyridin-4-yl)-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide149trans-N-((1r,4r)-4-((5- chloro-4-(1-(2-oxo-1,2- dihydropyridin-3-yl)-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide150cis-3-((5-fluoro-4-(3-(2- oxo-1,2-dihydropyridin-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide152(S)-3-(3-(2-((1- acetylpiperidin-3- yl)amino)-5- chloropyrimidin-4- yl)phenyl)pyridin-2(1H)- one153cis-N-((1s,4s)-4-((5-chloro- 4-(3-(2-oxo-1,2- dihydropyridin-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide154trans-N-((1r,4r)-4-((5- chloro-4-(3-(2-oxo-1,2- dihydropyridin-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide155trans-(1r,4r)-4-((5-chloro- 4-(3-(2-oxo-1,2- dihydropyridin-3- yl)phenyl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide156cis-3-((5-chloro-4-(3-(2- oxo-1,2-dihydropyridin-3- yl)phenyl)pyrimidin-2- yl)amino)-N- methylcyclobutane-1- carboxamide157(S)-6-(3-(2-((1- acetylpiperidin-3- yl)amino)-5- chloropyrimidin-4- yl)phenyl)pyridin-2(1H)- one158trans-N-((1r,4r)-4-((5- chloro-4-(6-(4- fluorophenyl)pyridin-2- yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide159trans-(1r,4r)-4-((5-chloro- 4-(6-(4- fluorophenyl)pyridin-2- yl)pyrimidin-2-yl)amino)- N-methylcyclohexane-1- carboxamide160trans-(1r,4r)-4-((5-chloro- 4-(2-(4- fluorophenyl)pyridin-4- yl)pyrimidin-2-yl)amino)- N-methylcyclohexane-1- carboxamide161cis-3-((5-chloro-4-(5- cyclopropyl-1H-pyrazol-3- yl)pyrimidin-2-yl)amino)- N-methylcyclobutane-1- carboxamide162trans-(1r,3r)-3-((5-chloro- 4-(5-cyclopropyl-1H- pyrazol-3-yl)pyrimidin-2- yl)amino)-N- methylcyclobutane-1- carboxamide163cis-(1s,4s)-4-((5-chloro-4- (1-(6-oxo-1,6- dihydropyridin-3-yl)-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide164cis-3-((5-chloro-4-(1-(6- oxo-1,6-dihydropyridin-3- yl)-1H-pyrazol-4- yl)pyrimidin-2-yl)amino)- N-methylcyclobutane-1- carboxamide165trans-(1r,4r)-4-((5-chloro- 4-(1-(2-oxo-1,2- dihydropyridin-4-yl)-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide166trans-(1r,3r)-3-((5-chloro- 4-(1-(2-oxo-1,2- dihydropyridin-3-yl)-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)-N- methylcyclobutane-1- carboxamide167cis-(1s,4s)-4-((5-chloro-4- (1-(6-oxo-1,6- dihydropyridin-2-yl)-1H- pyrazol-4-yl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide168cis-methyl 3-((5-chloro-4- (3-(4-fluoro-2-oxopyridin- 1(2H)- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxylate1691-(4-((5-fluoro-4-(3- (oxetan-3- yl)phenyl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one170cis-3-((5-fluoro-4-(3- (oxetan-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide1711-(4-((5-fluoro-4-(3-(3- hydroxyoxetan-3- yl)phenyl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one1721-(4-((5-fluoro-4-(2-(2- hydroxypropan-2- yl)pyridin-4-yl)pyrimidin- 2-yl)amino)piperidin-1- yl)ethan-1-one173cis-3-((5-fluoro-4-(3-(3- hydroxyoxetan-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide174trans-N-(4-((4-(3-(1- acetylpiperidin-3- yl)phenyl)-5- fluoropyrimidin-2- yl)amino)cyclohexyl) acetamide175N-(trans-4-((5-fluoro-4-(3- (oxetan-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide176N-(trans-4-((5-fluoro-4-(3- (3-hydroxyoxetan-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide177cis-3-((5-fluoro-4-(2-(2- hydroxypropan-2- yl)pyridin-4-yl)pyrimidin- 2-yl)amino)cyclohexane-1- carboxamide178cis-3-((4-(3-(1- acetylpiperidin-3- yl)phenyl)-5- fluoropyrimidin-2- yl)amino)cyclohexane-1- carboxamide1791-(4-((4-(3-(1- acetylpiperidin-3- yl)phenyl)-5- fluoropyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one180trans-4-((5-fluoro-4-(3- (oxetan-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide181trans-4-((5-fluoro-4-(3-(3- hydroxyoxetan-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide182trans-N-(4-((5-fluoro-4- morpholinopyrimidin-2- yl)amino)cyclohexyl) acetamide1874-(3-(2-((1-acetylpiperidin- 4-yl)amino)-5- fluoropyrimidin-4- yl)phenyl)pyridin-2(1H)- one188trans-N-(4-((5-fluoro-4-(3- (2-oxo-1,2-dihydropyridin- 4-yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide1891-(1-(2-((1-acetylpiperidin- 4-yl)amino)-5- fluoropyrimidin-4- yl)piperidin-3-yl)pyridin- 2(1H)-one190trans-N-((1r,4r)-4-((5- chloro-4-(5-cyclopropyl- 1H-pyrazol-3- yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide191cis-(1s,4s)-4-((5-chloro-4- (5-cyclopropyl-1H- pyrazol-3-yl)pyrimidin-2- yl)amino)-N- methylcyclohexane-1- carboxamide192(S)-1-(3-((5-chloro-4-(5- cyclopropyl-1H-pyrazol-3- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one193cis-3-((5-chloro-4-(1-(2- oxo-1,2-dihydropyridin-3- yl)-1H-pyrazol-4- yl)pyrimidin-2-yl)amino)- N-methylcyclobutane-1- carboxamide194(S)-1-(3-((5-chloro-4-(6- (4-fluorophenyl)pyridin-2- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one195trans-4-((5-fluoro-4-(3-(2- oxo-1,2-dihydropyridin-4- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide1963-[1-[2-[(1-acetyl-4- piperidyl)amino]-5-fluoro- pyrimidin-4-yl]-3- piperidyl]-1H-pyridin-2- one197trans-(R)-1-(2-((4- acetamidocyclohexyl) amino)-5-fluoropyrimidin- 4-yl)-N-cyclopropyl- piperidine-3-carboxamide198trans-(S)-1-(2-((4- acetamidocyclohexyl) amino)-5-fluoropyrimidin- 4-yl)-N-cyclopropyl- piperidine-3-carboxamide1995-(1-(2-((1-acetylpiperidin- 4-yl)amino)-5- fluoropyrimidin-4- yl)piperidin-3-yl)pyridin- 2(1H)-one200cis-3-((5-fluoro-4-(3-(2- oxo-1,2-dihydropyridin-4- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide201rac-(1S,3R)-3-((5-fluoro-4- (3-(6-oxo-1,6- dihydropyridin-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide2025-(3-(2-((1-acetylpiperidin- 4-yl)amino)-5- fluoropyrimidin-4- yl)phenyl)pyridin-2(1H)- one203trans-N-(4-((5-fluoro-4-(3- (6-oxo-1,6-dihydropyridin- 3-yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide204(1R,3S)-3-((5-fluoro-4-(3- (2-oxo-1,2-dihydropyridin- 3-yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide2051-(4-((5-fluoro-4- morpholinopyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one2064-(3-(2-((1-acetylpiperidin- 4-yl)amino)-5- fluoropyrimidin-4- yl)phenyl)morpholin-3-one207(1R,3S)-3-((5-fluoro-4-(3- (5-methyl-2-oxopyridin- 1(2H)- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide208(1R,3S)-3-((5-fluoro-4-(3- (2-oxo-5- (trifluoromethyl)pyridin- 1(2H)- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide209(R)-1-(4-((5-fluoro-4-(3- (3-hydroxypiperidin-1- yl)phenyl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one210(S)-1-(4-((5-fluoro-4-(3-(3- hydroxypiperidin-1- yl)phenyl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one2111-(4-((5-fluoro-4-(3-(4- hydroxypiperidin-1- yl)phenyl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one212(S)-1-(4-((5-fluoro-4-(3-(3- hydroxypyrrolidine-1- carbonyl)phenyl)pyrimidin- 2-yl)amino)piperidin-1- yl)ethan-1-one213(R)-1-(4-((5-fluoro-4-(3- (3-hydroxypyrrolidine-1- carbonyl)phenyl)pyrimidin- 2-yl)amino)piperidin-1- yl)ethan-1-one2141-(4-((5-fluoro-4-(3-(3- hydroxyazetidine-1- carbonyl)phenyl)pyrimidin- 2-yl)amino)piperidin-1- yl)ethan-1-one2151-(4-((5-fluoro-4-((S)-3- ((S)-3-hydroxypyrrolidine- 1-carbonyl)piperidin-1- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one2161-(4-((5-fluoro-4-((S)-3- ((R)-3-hydroxypyrrolidine- 1-carbonyl)piperidin-1- yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one2171-[4-[[5-fluoro-4-[3-[4- hydroxy-4- (hydroxymethyl)piperidine- 1- carbonyl]phenyl]pyrimidin- 2-yl]amino]-1- piperidyl]ethanone2181-(4-((4-(3-(4- (aminomethyl)-4- hydroxypiperidine-1- carbonyl)phenyl)-5- fluoropyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one2191-(4-((4-(4-cyclopropyl- 1H-pyrazol-1-yl)-5- fluoropyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one2203-[3-[2-[(1-acetyl-4- piperidyl)amino]-5-fluoro- pyrimidin-4-yl]phenyl]- 1,3-oxazinan-2-one2211-(3-(2-((1-acetylpiperidin- 4-yl)amino)-5- fluoropyrimidin-4- yl)phenyl)piperidin-2-one2221-[3-[2-[(1-acetyl-4- piperidyl)amino]-5-fluoro- pyrimidin-4- yl]phenyl]pyrrolidin-2-one223(1R,3S)-3-((5-fluoro-4-(3- (2-oxo-1,2-dihydropyridin- 3-yl)phenyl)pyrimidin-2- yl)amino)cyclopentane-1- carboxamide2244-(1-(2-((1-acetylpiperidin- 4-yl)amino)-5- fluoropyrimidin-4- yl)piperidin-3-yl)pyridin- 2(1H)-one225trans-N-(4-((5-fluoro-4-(3- (2-oxo-1,3-oxazinan-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide2263-(3-(2-((1-acetylpiperidin- 4-yl)amino)-5- fluoropyrimidin-4- yl)phenyl)oxazolidin-2-one227cis-3-((5-fluoro-4-(3-(2- oxo-1,3-oxazinan-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide2281-(3-(2-((1-acetylpiperidin- 4-yl)amino)-5- fluoropyrimidin-4- yl)phenyl)-3- hydroxypyrrolidin-2-one229trans-4-((5-fluoro-4-(3-(6- oxo-1,6-dihydropyridin-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide230(4S)-1-[3-[2-[(1-acetyl-4- piperidyl)amino]-5-fluoro- pyrimidin-4-yl]phenyl]-4- hydroxy-pyrrolidin-2-one231trans-N-(4-((5-fluoro-4-(2- (1- hydroxycyclobutyl)pyridin- 4-yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide2321-(4-((5-fluoro-4-(2-(1- hydroxycyclobutyl)pyridin- 4-yl)pyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one233trans-N-(4-((5-fluoro-4-(3- (2-oxooxazolidin-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide234trans-N-(4-((5-fluoro-4-(3- (2-oxo-5- (trifluoromethyl)pyridin- 1(2H)- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide235trans-N-(4-((5-fluoro-4-(3- (5-methyl-2-oxopyridin- 1(2H)- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide236trans-4-((5-fluoro-4-(3-(2- oxo-1,3-oxazinan-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide237(4R)-1-[3-[2-[(1-acetyl-4- piperidyl)amino]-5-fluoro- pyrimidin-4-yl]phenyl]-4- hydroxy-pyrrolidin-2-one238trans-N-[4-[[5-fluoro-4-[3- (2-oxo-1- pyridyl)phenyl]pyrimidin- 2-yl]amino]cyclohexyl] acetamide2391-(4-((4-(3-(1H-imidazol- 2-yl)phenyl)-5- fluoropyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one240trans-(1r,4r)-4-((5-fluoro- 4-(3-(2-oxopyridin-1(2H)- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide241trans-N-(4-((5-fluoro-4-(2- (2-hydroxypropan-2- yl)pyridin-4-yl)pyrimidin- 2-yl)amino)cyclohexyl) acetamide242trans-4-((5-fluoro-4-(2-(2- hydroxypropan-2- yl)pyridin-4-yl)pyrimidin- 2-yl)amino)cyclohexane-1- carboxamide243trans-4-((5-fluoro-4-(2-(1- hydroxycyclobutyl)pyridin- 4-yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide244(1R,3S)-3-((5-fluoro-4-(2- (1- hydroxycyclobutyl)pyridin- 4-yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide245trans-4-((5-fluoro-4-(3-(2- oxooxazolidin-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide246trans-4-((5-fluoro-4-(3-(2- oxo-5- (trifluoromethyl)pyridin- 1(2H)-yl)phenyl) pyrimidin-2-yl)amino) cyclohexane-1- carboxamide247trans-4-((5-fluoro-4-(3-(5- methyl-2-oxopyridin- 1(2H)- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide248trans-N-(4-((5-fluoro-4-(3- (2-oxopyrrolidin-1- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide249trans-4-((5-fluoro-4-(3-(2- oxopyrrolidin-1- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide250trans-N-(4-((5-fluoro-4-(3- (4-hydroxypiperidin-1- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide251trans-4-((5-fluoro-4-(3-(4- hydroxypiperidin-1- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide252trans-N-[4-[[5-fluoro-4-[3- [(3S)-3- hydroxypyrrolidine-1- carbonyl]phenyl] pyrimidin-2-yl]amino] cyclohexyl]acetamide253trans-N-((1r,4r)-4-((5- fluoro-4-(2-(2- oxooxazolidin-3- yl)pyridin-4-yl)pyrimidin- 2-yl)amino)cyclohexyl) acetamide254trans-(1r,4r)-4-((5-fluoro- 4-(3-(2-oxo-1,2- dihydropyridin-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide255N-(trans-4-((5-fluoro-4-(3- (2-oxo-1,2-dihydropyridin- 3-yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide256trans-N-(4-((5-fluoro-4-(3- (2-oxopiperidin-1- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide257trans-N-(-4-((5-fluoro-4-(2- (2-oxopiperidin-1- yl)pyridin-4-yl)pyrimidin- 2-yl)amino)cyclohexyl) acetamide258trans-4-((5-fluoro-4-(2-(2- oxopiperidin-1-yl)pyridin- 4-yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide259trans-(S)-4-((5-fluoro-4-(3- (3-hydroxypyrrolidine-1- carbonyl)phenyl)pyrimidin- 2-yl)amino)cyclohexane- 1-carboxamide260trans-N-((1r,4r)-4-((5- fluoro-4-(4-(2-oxopyridin- 1(2H)-yl)-1H-pyrazol-1- yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide261trans-N-(4-((5-fluoro-4-(2- (2-oxopyrrolidin-1- yl)pyridin-4-yl)pyrimidin- 2-yl)amino)cyclohexyl) acetamide262trans-(1r,4r)-4-((5-fluoro- 4-(2-(2-oxopyrrolidin-1- yl)pyridin-4-yl)pyrimidin- 2-yl)amino)cyclohexane- 1-carboxamide263trans-4-((5-fluoro-4-(2-(2- oxooxazolidin-3- yl)pyridin-4-yl)pyrimidin- 2-yl)amino)cyclohexane-1- carboxamide264trans-4-((5-fluoro-4-(3-(2- oxopiperidin-1- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide265trans-N-(4-((5-fluoro-4-(2- oxo-2H-[1,2′-bipyridin]-4′- yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide266trans-N-(4-((5-fluoro-4-(2- (2-oxo-1,3-oxazinan-3- yl)pyridin-4-yl)pyrimidin- 2-yl)amino)cyclohexyl) acetamide267trans-N-(4-((5-fluoro-4-(3- (3- oxomorpholino)phenyl) pyrimidin-2-yl)amino) cyclohexyl)acetamide268trans-4-((5-fluoro-4-(3-(3- oxomorpholino)phenyl) pyrimidin-2-yl)amino) cyclohexane-1- carboxamide269cis-3-((5-fluoro-4-(3-(3- oxomorpholino)phenyl) pyrimidin-2-yl) amino)cyclohexane-1- carboxamide270trans-N-(4-((5-fluoro-4-(6- (3-oxomorpholino)pyridin- 2-yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide271trans-4-((5-fluoro-4-(6-(3- oxomorpholino)pyridin-3- yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide272trans-N-(4-((5-fluoro-4-(2- (3-oxomorpholino)pyridin- 4-yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide273trans-4-((5-fluoro-4-(2-(3- oxomorpholino)pyridin-4- yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide274trans-4-((5-fluoro-4-(6-(2- oxopiperidin-1-yl)pyridin- 2-yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide6061-[4-[[5-fluoro-4-(3- morpholinophenyl) pyrimidin-2-yl]amino]-1- piperidyl]ethanone607trans-4-((5-fluoro-4-(3- morpholinophenyl) pyrimidin-2-yl)amino) cyclohexane-1- carboxamide608trans-N-(4-((5-fluoro-4-(3- morpholinophenyl) pyrimidin-2-yl)amino) cyclohexyl)acetamide609trans-N-(4-((4-([1,1′- biphenyl]-3-yl)-5- fluoropyrimidin-2- yl)amino)cyclohexyl) acetamide610trans-4-((4-([1,1′- biphenyl]-3-yl)-5- fluoropyrimidin-2- yl)amino)cyclohexane-1- carboxamide6111-(4-((4-([1,1′-biphenyl]-3- yl)-5-fluoropyrimidin-2- yl)amino)piperidin-1- yl)ethan-1-one612(1R,3S)-3-((4-([1,1′- biphenyl]-3-yl)-5- fluoropyrimidin-2-yl) amino)cyclohexane-1- carboxamide613(S)-1-(3-(2-((1- acetylpyrrolidin-3- yl)amino)-5- fluoropyrimidin-4- yl)phenyl)pyridin-2(1H)- one6141-(3-(2-((1-acetylpiperidin- 4-yl)amino)-5- fluoropyrimidin-4- yl)phenyl)pyridin-2(1H)- one615trans-4-((5-fluoro-4-(3- (piperidin-1- yl)phenyl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide616trans-N-(4-((5-fluoro-4-(3- (piperidin-1- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamide617trans-4-((5-fluoro-4-(2- oxo-2H-[1,2′-bipyridin]-6′- yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide618trans-(1r,4r)-4-((4-(3- cyclopropylphenyl)-5- fluoropyrimidin-2- yl)amino)cyclohexane-1- carboxamide619trans-N-((1r,4r)-4-((4-(3- cyclopropylphenyl)-5- fluoropyrimidin-2- yl)amino)cyclohexyl) acetamide620trans-4-((5-fluoro-4-(6-(1- hydroxycyclobutyl)pyridin- 2-yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide621trans-4-((5-fluoro-4-(6-(2- oxo-1,3-oxazinan-3- yl)pyridin-2-yl)pyrimidin- 2-yl)amino)cyclohexane-1- carboxamide622trans-4-[[5-fluoro-4-[2-(2- oxo-1,3-oxazinan-3-yl)-4- pyridyl]pyrimidin-2- yl]amino]cyclohexane- carboxamide623trans-4-((5-fluoro-4-(2- oxo-2H-[1,2′-bipyridin]-4′- yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide624N-(trans-4-((5-fluoro-4-(6- (2-oxo-1,3-oxazinan-3- yl)pyridin-2-yl)pyrimidin- 2-yl)amino)cyclohexyl) acetamide625N-(trans-4-((5-fluoro-4-(6- (2-oxopiperidin-1-yl) pyridin-2-yl)pyrimidin- 2-yl)amino)cyclohexyl) acetamide626trans-N-(4-((5-fluoro-4-(2- oxo-2H-[1,2′-bipyridin]-6′- yl)pyrimidin-2- yl)amino)cyclohexyl) acetamide627cis-3-((5-fluoro-4-(6-(3- oxomorpholino)pyridin-2- yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide6284-(4-(2-((1-acetylpiperidin- 4-yl)amino)-5- fluoropyrimidin-4- yl)pyridin-2-yl)morpholin- 3-one629cis-3-((5-fluoro-4-(2-(3- oxomorpholino)pyridin-4- yl)pyrimidin-2- yl)amino)cyclohexane-1- carboxamide6304-(6-(2-((1-acetylpiperidin- 4-yl)amino)-5- fluoropyrimidin-4- yl)pyridin-2-yl)morpholin- 3-one631N-(trans-4-((5-fluoro-4-(3- (6-oxopiperidin-3- yl)phenyl)pyrimidin-2- yl)amino)cyclohexyl) acetamideTABLE 2Representative Compounds of Formula (I′), (I), and (IV)Co. No.Structure and Name 443-(5-(1-(2-(4-((S)-3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-1-yl)ethyl)-piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 453-[5-[1-[2-[4-[4-[[5-chloro-4-(3-phenylphenyl)pyrimidin-2-yl]amino]piperidine-1-carbonyl]-1-piperidyl]ethyl]-4-piperidyl]-3-methyl-2-oxo-benzimidazol-1-yl]piperidine-2,6-dione 463-(5-(1-(2-(4-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-1-yl)acetyl)-piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 473-(5-(1-((1-(2-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)-methyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 483-((4-(1′-(3-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropyl)-[1,4′-bipiperidin]-4-yl)phenyl)amino)piperidine-2,6-dione 49cis-3-(5-(1-(2-(4-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)-ethyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 503-[5-[1-[[1-[2-[4-[5-chloro-4-(3-phenylphenyl)pyrimidin-2-yl]amino]-1-piperidyl]-2-oxo-ethyl]-4-piperidyl]methyl]-4-piperidyl]-1-oxo-indan-2-yl]piperidine-2,6-dione 51cis-3-(5-(1-(2-(4-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 52cis-3-(5-(1-(2-(1-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)-ethyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 533-((4-(1-((1-(2-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)-methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione 54cis-3-(5-(1-(2-(4-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 55cis-3-((4-(1-(2-(4-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)ethyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione 563-(5-(1-(2-(4-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-1-yl)acetyl)-piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 57cis-3-((4-(1-(2-(4-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione 58cis-3-(5-(1-(2-(4-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)-acetyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 59cis-3-(5-(1-(2-(1-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)-acetyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 60cis-3-(5-(1-(1-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 61cis-3-(5-(1-(2-(4-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)-ethyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 62cis-3-(5-(1-(2-(1-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 63cis-3-(5-(1-((1-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)-methyl)piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 64cis-3-((4-(1-(2-(1-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione 65cis-3-((4-(1-((1-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)-methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione 66N-(10-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-10-oxodecyl)-2-((2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide 67N-(3-(4-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-1-yl)-3-oxopropyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)acetamide 68N-(4-(4-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-1-yl)-4-oxobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)oxy)acetamide 69N-(5-(4-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-1-yl)-5-oxopentyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)acetamide 703-(5-(1′-(2-((S)-3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-[1,4′-bipiperidin]-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 713-(5-(1′-(2-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-[1,4′-bipiperidin]-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 723-(5-(1′-(2-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-[1,4′-bipiperidin]-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 733-(5-(1-((1-(2-((S)-3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 743-((4-(1-(2-(4-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-1-yl)ethyl)-piperidin-4-yl)phenyl)amino)piperidine-2,6-dione 753-(5-(1′-(2-((S)-3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-[1,4′-bipiperidin]-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione 76cis-3-(5-((1-((1-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 77cis-3-(5-((1-(1-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 783-(5-(1-(2-(4-((S)-3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-1-yl)-ethyl)piperidin-4-yl)-1-oxo-2,3-dihydro-1H-inden-2-yl)piperidine-2,6-dione 79cis-3-(5-((1-(2-(1-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)-ethyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 80cis-3-(5-((1-(2-(4-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)ethyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 81cis-3-(5-((1-(2-(1-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)acetyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 82cis-3-(5-((1-(2-(4-(3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)acetyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 833-(5-((1-(2-(4-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-1-yl)-acetyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 843-((4-(4-(4-(3-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropyl)piperazin-1-yl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione 853-(5-((1-((1-(2-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 863-(5-(1′-(3-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropyl)-[1,4′-bipiperidin]-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 873-(5-((1′-(2-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-[1,4′-bipiperidin]-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 883-(5-(1-(2-(4-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-1-yl)ethyl)-piperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 893-(5-((1-(2-(4-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-1-yl)ethyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 903-(5-((1′-(3-(4-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropyl)-[1,4′-bipiperidin]-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione2753-(5-(1′-(2-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-[1,3′-bipiperidin]-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione276trans-N-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)cyclohexyl)-2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)piperidin-1-yl)methyl)piperidin-1-yl)acetamide2773-(6-(1-((1-(2-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione2783-(6-(1-(1-(2-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-4-hydroxypiperidine-4-carbonyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione279rac-3-(5-(1-(2-(1-((1S,3R)-3-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)cyclohexane-1-carbon-yl)piperidin-4-yl)ethyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione2803-(5-(1-(2-(1-((1R,3S)-3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione2813-(5-(1-(2-(1-((1S,3R)-3-((4-([1,1′-biphenyl]-3-yl)-5-chloropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione2823-(4-(4-(2-(4-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-1-yl)-2-oxoethyl)-4-hydroxypiperidin-1-yl)-3-fluorophenyl)piperidine-2,6-dione283rac-3-(4-(4-(1-((1S,3R)-3-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-piperidin-4-yl)piperazin-1-yl)-3-fluorophenyl)piperidine-2,6-dione284cis-3-((4-(1-(2-(2-(3-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-2,6-diazaspiro[3.4]octan-6-yl)-2-oxoethyl)piperidin-4-yl)-3-fluorophenyl)amino)piperidine-2,6-dione285trans-N-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)cyclohexyl)-1′-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-[1,4′-bipiperidine]-4-carboxamide2863-(5-(1-((1-(2-(4-((4-([1,1′-biphenyl]-3-yl)-5-fluoropyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)-methyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione2873-(5-(1-((1-(2-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione2883-(5-(1-((1-(2-(4-((5-fluoro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione2893-(6-(1-(2-(4-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)-4-hydroxy-piperidin-1-yl)acetyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione2903-(6-(1-(2-(4-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)-4-hydroxy-piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione291rac-3-(5-(1-(2-(1-((1S,3R)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione292rac-3-(4-(4-(2-(4-((1S,3R)-3-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)-2-oxoethyl)-4-hydroxypiperidin-1-yl)-3-fluorophenoxy)piperidine-2,6-dione2933-(7-(1-(2-(4-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-1-yl)acetyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione2943-(6-(1-((1-(2-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione295rac-3-(6-(1-(2-(1-((1S,3R)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione2963-(4-((1′-(2-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-[1,3′-bipiperidin]-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione297rac-(1S,3R)-N-((1′-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)-[1,4′-bipiperidin]-4-yl)methyl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide2983-(6-(1-(2-(1-(cis-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione299rac-(1S,3R)-N-((1′-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-[1,4′-bipiperidin]-4-yl)-methyl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide3003-(5-(1′-(3-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropyl)-[1,4′-bipiperidin]-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione301trans-2-(4-((4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)piperidin-1-yl)meth-yl)piperidin-1-yl)-N-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide302trans-2-(4-((4-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)piperidin-1-yl)methyl)piperidin-1-yl)-N-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide3033-(6-(1-((1-(2-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-piperidin-4-yl)methyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione304trans-2-(4-((4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperidin-1-yl)methyl)piperidin-1-yl)-N-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide305trans-1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-N-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)-pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide306cis-trans-N-(4-((4-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)piperidin-1-yl)methyl)-cyclohexyl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide307cis-trans-N-(4-((4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperidin-1-yl)methyl)cyclohexyl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide3083-((3-fluoro-4-(1-(2-(1-((1R,3S)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclo-hexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione3093-((3-fluoro-4-(1-(2-(1-((1S,3R)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione3103-[4-[3,3-difluoro-1-[2-[1-[(1R,3S)-3-[[5-fluoro-4-[3-(2-oxo-1-pyridyl)phenyl]pyrimidin-2-yl]amino]cyclohexane-carbonyl]-4-piperidyl]ethyl]-4-piperidyl]-3-fluoro-anilino]piperidine-2,6-dione3113-((4-(3,3-difluoro-1-(2-(1-((1S,3R)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)-3-fluorophenyl)amino)piperidine-2,6-dione3123-(5-(1-((1-(2-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-piperidin-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione313trans-2-(4-((4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)methyl)piperidin-1-yl)-N-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide3143-((3-fluoro-4-(1-((1-(2-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione3153-(6-(1-((1-(2-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione316trans-1-[2-[1-[4-[(2,6-dioxo-3-piperidyl)amino]-2-fluoro-phenyl]-4-piperidyl]ethyl]-N-[4-[[5-fluoro-4-[3-(2-oxo-1-pyridyl)phenyl]pyrimidin-2-yl]amino]cyclohexyl]piperidine-4-carboxamide317trans-1′-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)-N-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide318trans-3-((3-fluoro-4-(1-((1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione319trans-trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide320cis-N-(1-((1-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)piperidin-4-yl)methyl)piperidin-4-yl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide321trans-3-(6-(1-(2-(1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-piperidin-4-yl)ethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione322trans-3-((3-fluoro-4-(1-(2-(1-((1r,4r)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclo-hexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione323trans-3-(6-(1-((1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-piperidin-4-yl)methyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione324trans-N-(cis-4-((4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)methyl)cyclohexyl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide325cis-3-(6-(1-(2-(1-(3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclobutane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione326trans-2-(4-((4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)methyl)piperidin-1-yl)-N-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide327trans-2-[4-[[1-[4-[(2,6-dioxo-3-piperidyl)amino]-2-fluoro-phenyl]-4-piperidyl]methyl]piperazin-1-yl]-N-[4-[[5-fluoro-4-[3-(2-oxo-1-pyridyl)phenyl]pyrimidin-2-yl]amino]cyclohexyl]acetamide328trans-3-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-[1,4′-bipiperidin]-1′-yl)-N-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)propanamide329trans-1-[2-[1-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-6-yl]-4-piperidyl]ethyl]-N-[4-[[5-fluoro-4-[3-(2-oxo-1-pyridyl)phenyl]pyrimidin-2-yl]amino]cyclohexyl]piperidine-4-carboxamide3303-[6-[4-[2-[4-[4-[5-fluoro-4-[3-(2-oxo-1-pyridyl)phenyl]pyrimidin-2-yl]amino]piperidine-1-carbonyl]-1-piperidyl]ethyl]-1-piperidyl]-2-oxo-1,3-benzoxazol-3-yl]piperidine-2,6-dione3313-(6-(1-(2-(4-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)-4-hydroxy-piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione332cis-N-(1-((1-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperidin-4-yl)methyl)piperidin-4-yl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide333cis-N-((1′-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)-[1,4′-bipiperidin]-4-yl)methyl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide334cis-trans-N-((4-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperidin-1-yl)cyclohexyl)methyl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide3353-(5-(1-(2-(1-((1R,3S)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbon-yl)piperidin-4-yl)ethyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione336cis-N-(1-((1-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-4-yl)methyl)piperidin-4-yl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide337cis-N-((cis-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)methyl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide338trans-3-(5-(1-(2-(4-(4-((5-chloro-4-(4′-fluoro-[1,1′-biphenyl]-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)cyclo-hexyl)ethyl)piperidin-4-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione339trans-2-(4-((4-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)piperazin-1-yl)methyl)piperidin-1-yl)-N-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide3403-(6-(4-((1-(2-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-piperidin-4-yl)methyl)piperazin-1-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3413-((3-fluoro-4-(4-((1-(2-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione342cis-3-(6-(4-(2-(1-(3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-piperidin-4-yl)ethyl)piperazin-1-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3433-((3-fluoro-4-(1′-(3-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropyl)-[1,4′-bipiperidin]-4-yl)phenyl)amino)piperidine-2,6-dione344trans-1′-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-N-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide345trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)-N-(trans-4-((5-fluoro-4-(3-(2-oxo-pyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide3461-(6-(1-(2-(4-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)-4-hydroxypiperidin-1-yl)-2-oxoethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)dihydropyrimidine-2,4(1H,3H)-dione347cis-3-(6-(1-(2-(1-(3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-hydroxypiperidin-4-yl)ethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione348cis-3-((3-fluoro-4-(1-(2-(1-(3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-hydroxypiperidin-4-yl)ethyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione349cis-trans-N-((4-(4-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)piperidin-1-yl)cyclohexyl)meth-yl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide3503-(6-(1-(2-(1-((1R,3S)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbon-yl)piperidin-4-yl)ethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3513-(6-(1-(2-(1-((1R,3S)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione352cis-N-((trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)methyl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide3533-(6-(1′-(3-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropyl)-[1,4′-bipiperidin]-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3543-(6-(1-(2-(1-((1R,3S)-3-((5-fluoro-4-(3-(5-methyl-2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3553-(6-(1-(2-(1-((1R,3S)-3-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3563-(6-(1-(2-(1-((1R,3S)-3-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-piperidin-4-yl)ethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3573-(6-(1-(2-(1-((1R,3S)-3-((5-fluoro-4-(3-(2-oxo-5-(trifluoromethyl)pyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)-cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione358trans-2-(1-((1-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)piperidin-4-yl)methyl)piperidin-4-yl)-N-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide359trans-N-(4-((4-(1-(cyclopropanecarbonyl)piperidin-3-yl)-5-fluoropyrimidin-2-yl)amino)cyclohexyl)-2-(4-((4-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)piperidin-1-yl)methyl)piperidin-1-yl)acetamide3602-(4-((1-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)piperidin-4-yl)methyl)piperazin-1-yl)-N-(trans-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide361cis-N-((1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-[1,4′-bipiperidin]-4-yl)methyl)-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide362trans-2-(4-((4-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)piperidin-1-yl)methyl)piperidin-1-yl)-N-(4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide363trans-2-[4-[[4-[3-(2,6-dioxo-3-piperidyl)-2-oxo-1,3-benzoxazol-6-yl]-1-piperidyl]methyl]-1-piperidyl]-N-[4-[[5-fluoro-4-[3-(2-oxooxazolidin-3-yl)phenyl]pyrimidin-2-yl]amino]cyclohexyl]acetamide3643-((3-fluoro-4-(1-((1-(2-(4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione365trans-2-(4-((4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)methyl)piperidin-1-yl)-N-(4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide3663-(6-(1-((1-(2-(4-((4-([1,1′-biphenyl]-3-yl)-5-fluoropyrimidin-2-yl)amino)-2-oxopiperidin-1-yl)acetyl)piperidin-4-yl)-methyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3673-(6-(1-((1-(2-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)-2-oxopiperidin-1-yl)acetyl)-piperidin-4-yl)methyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3683-(6-(1-(2-(1-(trans-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)ethyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione369trans-N-(4-((5-chloro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)-2-(4-((4-(3-(2,6-dioxo-piperidin-3-yl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)piperidin-1-yl)methyl)piperidin-1-yl)acetamide3703-(6-(1-((1-(1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-1-oxopropan-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3713-(6-(1-((1-(2-(4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-piperidin-4-yl)methyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3723-(6-(1-((1-(2-(4-((5-fluoro-4-(3-(2-oxooxazolidin-3-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-piperidin-4-yl)methyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3733-(6-(1-((1-(2-(4-((5-chloro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-piperidin-4-yl)methyl)piperidin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione374trans-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione375trans-N-(1-((1-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-4-yl)methyl)piperidin-4-yl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide376trans-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione377trans-2-(1-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-4-yl)-2-azaspiro[3.3]heptan-6-yl(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)carbamate3783-(6-(4-((4-(2-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-piperazin-1-yl)methyl)piperidin-1-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3793-[6-[1-[[1-[2-[4-[5-fluoro-4-[3-(2-oxo-1H-pyridin-3-yl)phenyl]pyrimidin-2-yl]amino]-1-piperidyl]-2-oxo-ethyl]-4-piperidyl]methyl]-4-piperidyl]-2-oxo-1,3-benzoxazol-3-yl]piperidine-2,6-dione3803-(6-(4-((4-(2-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidin-1-yl)-2-oxoethyl)-4-hydroxypiperidin-1-yl)methyl)piperidin-1-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione381trans-(1r,4R)-N-((1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide382trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide383trans-N-(trans-4-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide384trans-3-((3-fluoro-4-(1-((1-(4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione385trans-3-(6-(1-((1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-piperidin-4-yl)methyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione3863-(6-(4-(2-(4-(cis-3-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-piperazin-1-yl)ethyl)piperidin-1-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione387trans-3-((3-fluoro-4-(4-((4-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)methyl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione388trans-4-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperazin-1-yl)-N-(trans-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide389trans-(1r,4R)-4-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperazin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide390trans-3-[4-[3,3-difluoro-1-[[1-[4-[[5-fluoro-4-[3-(2-oxo-1-pyridyl)phenyl]pyrimidin-2-yl]amino]cyclohexanecarbonyl]-4-piperidyl]methyl]-4-piperidyl]-3-fluoro-anilino]piperidine-2,6-dione391trans-3-(6-(1-((1-(4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione392trans-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione393trans-3-[3-fluoro-4-[4-[[1-[4-[5-fluoro-4-[3-(2-oxo-1-piperidyl)phenyl]pyrimidin-2-yl]amino]cyclohexanecarbonyl]-4-piperidyl]methyl]piperazin-1-yl]anilino]piperidine-2,6-dione394trans-3-((3-fluoro-4-(1-((1-(4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione395trans-2-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-[1,4′-bipiperidin]-4-yl)-N-((1r,4r)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide396trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)-N-(trans-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide397trans-3-(6-(4-((1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-piperidin-4-yl)methyl)piperazin-1-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione398trans-3-(6-(4-((1-(4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6-dione3993-(6-(4-((1-(trans-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-piperidin-4-yl)methyl)piperazin-1-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione400trans-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione401trans-(1r,4R)-N-((1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide402trans-(1r,4R)-N-((1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide403trans-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)oxy)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione404trans-(1r,4R)-N-((1r,4R)-4-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide4051′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′-fluoro-N-((1r,4r)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)-phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide4061′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′-fluoro-N-((1r,4r)-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydro-pyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide407trans-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione408trans-3-[4-[3,3-difluoro-1-[1-[4-[5-fluoro-4-[3-(2-oxo-1H-pyridin-3-yl)phenyl]pyrimidin-2-yl]amino]cyclohexane-carbonyl]-4-piperidyl]methyl]-4-piperidyl]-3-fluoro-anilino]piperidine-2,6-dione409trans-3-((3-fluoro-4-(1-((1-(-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione410trans-3-((3-fluoro-4-(4-((4-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)methyl)-4-hydroxypiperidin-1-yl)phenyl)amino)piperidine-2,6-dione411trans-(1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxooxazolidin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide412trans-(1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide413trans-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)oxy)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione414trans-3-((3-fluoro-4-(4-((1-(-4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione415trans-3-((3-fluoro-4-(4-((4-(4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)methyl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione416trans-N-((trans-4-((4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)methyl)cyclohexyl)methyl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide4173-(6-(4-((1-(trans-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione418trans-(1r,4R)-N-((1R,4R)-4-(4-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide419trans-(1r,4R)-N-((1R,4R)-4-(4-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide420trans-(1r,4R)-N-((1R,4R)-4-(4-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide421trans-(R)-3-((3-fluoro-4-(1-((1-(-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclo-hexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione422trans-(R)-3-(6-(1-((1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione423trans-(R)-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione424trans-(1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide425trans-3-((3-fluoro-4-(4-((1-(-4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione426trans-3-[3-fluoro-4-[4-[[1-[4-[[5-fluoro-4-[3-(2-oxo-1,3-oxazinan-3-yl)phenyl]pyrimidin-2-yl]amino]cyclohexane-carbonyl]-4-piperidyl]methyl]piperazin-1-yl]anilino]piperidine-2,6-dione427trans-3-((3-fluoro-4-(1-((1-(4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione428trans-3-((3-fluoro-4-(4-((4-(4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperazin-1-yl)methyl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione429trans-1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-N-(4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide4303-((3-fluoro-4-(4-((4-(trans-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclo-hexane-1-carbonyl)piperazin-1-yl)methyl)piperidin-1-yl)phenyl)amino)piperidine-2,6-dione431trans-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′,3′-difluoro-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide432trans-(1r,4R)-N-((1R,4R)-4-(4-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide4331-((1-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-4-yl)methyl)-N-((1r,4r)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)piperidine-4-carboxamide434trans-(1r,4R)-N-((1S,4R)-4-(4-(4-(((S)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide435trans-(1r,4R)-N-((1S,4R)-4-(4-(4-(((S)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide436trans-(1r,4R)-N-((1S,4R)-4-(4-(4-(((S)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide437trans-(S)-3-((3-fluoro-4-(1-((1-(-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclo-hexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione438trans-(S)-3-(6-(1-((1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)-1-methyl-1H-indazol-3-yl)piperidine-2,6-dione439trans-(S)-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione440trans-N-(1′-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide441trans-(1r,4R)-N-((1S,4R)-4-(4-(4-(((S)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide442trans-(R)-3-((3-fluoro-4-(1-((1-(-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione443trans-(S)-3-((3-fluoro-4-(1-((1-(-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione444trans-1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-N-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)-pyrimidin-2-yl)amino)cyclohexyl)-4-hydroxy-[1,4′-bipiperidine]-4-carboxamide445trans-(1R,4R)-4-(4-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide446trans-(1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxooxazolidin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide447trans-(1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide448trans-(R)-3-((3-fluoro-4-(1-((1-((1r,4r)-4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclo-hexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione449trans-(S)-3-((3-fluoro-4-(1-((1-((1r,4r)-4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione450trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-(trans-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide451trans-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′,3′-difluoro-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide452trans-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′-fluoro-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide453trans-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′-fluoro-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide454trans-4-(4-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)-N-(trans-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide455trans-(R)-3-((3-fluoro-4-(1-((1-((1r,4r)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclo-hexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione456trans-(S)-3-((3-fluoro-4-(1-((1-((1r,4r)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclo-hexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione457(1S,4R)-4-(4-(4-(((S)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide458trans-(1S,4R)-4-(4-(4-(((S)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide459(1r,4R)-N-(((1R,4R)-4-((4-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)methyl)cyclohexyl)-methyl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide460(1r,4R)-N-(((1S,4R)-4-((4-(4-(((S)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)methyl)cyclohexyl)-methyl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide461trans-(1R,4R)-4-(4-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide462trans-(1S,4R)-4-(4-(4-(((S)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide463trans-3-[3-fluoro-4-[4-[[1-[4-[[5-fluoro-4-(3-phenylphenyl)pyrimidin-2-yl]amino]cyclohexanecarbonyl]-4-hydroxy-4-piperidyl]methyl]piperazin-1-yl]anilino]piperidine-2,6-dione4643-((4-(1-((1-(trans-4-((4-([1,1′-biphenyl]-3-yl)-5-fluoropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-hydroxy-piperidin-4-yl)methyl)piperidin-4-yl)-3-fluorophenyl)amino)piperidine-2,6-dione4653-((3-fluoro-4-(1-((1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione4663-((4-(1-((1-(trans-4-((4-([1,1′-biphenyl]-3-yl)-5-fluoropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)-methyl)piperidin-4-yl)-3-fluorophenyl)amino)piperidine-2,6-dione467trans-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl 4-((4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperidin-1-yl)methyl)piperidine-1-carboxylate468trans-3-((3-fluoro-4-(1-((1-(4-((5-fluoro-4-(3-((S)-3-hydroxypyrrolidine-1-carbonyl)phenyl)pyrimidin-2-yl)amino)-cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione469trans-4-((4-([1,1′-biphenyl]-3-yl)-5-fluoropyrimidin-2-yl)amino)cyclohexyl 4-(2-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)ethyl)piperidine-1-carboxylate470trans-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-(4-methyl-2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclo-hexane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione471trans-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-(4-methyl-2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclo-hexane-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione472trans-3-[3-fluoro-4-[1-[[1-[4-[[5-fluoro-4-[3-(4-methyl-2-oxo-1-pyridyl)phenyl]pyrimidin-2-yl]amino]cyclohexane-carbonyl]-4-hydroxy-4-piperidyl]methyl]-4-piperidyl]anilino]piperidine-2,6-dione473trans-3-((3-fluoro-4-(1-((1-(4-((5-fluoro-4-(3-(4-methyl-2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclo-hexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione474trans-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl 4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-[1,4′-bipiperidine]-1′-carboxylate475trans-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl 4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)piperidine-1-carboxylate476trans-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′-fluoro-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(3-oxomorpholino)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide477trans-3-((3-fluoro-4-(1-((1-(trans-4-((5-fluoro-4-(3-(piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione478trans-N-((trans)-4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2-yl)amino)cyclohexyl)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-methylcyclohexane-1-carboxamide479trans-N-((trans)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(6-(1-hydroxycyclobutyl)pyridin-2-yl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide480trans-N-((trans)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(2-(3-oxomorpholino)pyridin-4-yl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide481trans-3-((3-fluoro-4-(1-((1-(4-((5-fluoro-4-(3-((S)-3-hydroxypyrrolidine-1-carbonyl)phenyl)pyrimidin-2-yl)amino)-cyclohexane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione482trans-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-((S)-3-hydroxypyrrolidine-1-carbonyl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione483trans-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-((S)-3-hydroxypyrrolidine-1-carbonyl)phenyl)pyrimidin-2-yl)amino)-cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione484trans-3-[3-fluoro-4-[4-[[4-fluoro-1-[4-[[5-fluoro-4-(3-phenylphenyl)pyrimidin-2-yl]amino]cyclohexanecarbonyl]-4-piperidyl]methyl]piperazin-1-yl]anilino]piperidine-2,6-dione485trans-3-((4-(4-((1-(4-((4-([1,1′-biphenyl]-3-yl)-5-fluoropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)-methyl)piperazin-1-yl)-3-fluorophenyl)amino)piperidine-2,6-dione486trans-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′-fluoro-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide487trans-3-((3-fluoro-4-(1-((4-fluoro-1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclo-hexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione488trans-(1r,4R)-N-((1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)-N-methylcyclohexane-1-carboxamide489trans-(1r,4R)-4-((4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperazin-1-yl)methyl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide490trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide491trans-3-((3-fluoro-4-(4-((4-fluoro-1-(4-((5-fluoro-4-(3-(piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione492trans-3-((4-(4-((1-(4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-hydroxy-piperidin-4-yl)methyl)piperazin-1-yl)-3-fluorophenyl)amino)piperidine-2,6-dione493trans-3-[3-fluoro-4-[4-[[1-[4-[5-fluoro-4-[3-(1-piperidyl)phenyl]pyrimidin-2-yl]amino]cyclohexanecarbonyl]-4-hydroxy-4-piperidyl]methyl]piperazin-1-yl]anilino]piperidine-2,6-dione494trans-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′,3′-difluoro-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide495trans-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′,3′-difluoro-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide496trans-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′,3′-difluoro-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(3-oxomorpholino)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide497trans-N-(4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2-yl)amino)cyclohexyl)-1′-(4-((2,6-dioxopiperidin-3-yl)-amino)-2-fluorophenyl)-3′,3′-difluoro-[1,4′-bipiperidine]-4-carboxamide498trans-1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′,3′-difluoro-N-(4-((5-fluoro-4-(3-(piperidin-1-yl)phen-yl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide499trans-1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′,3′-difluoro-N-(4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide500trans-1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′,3′-difluoro-N-(4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide501trans-1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′,3′-difluoro-N-(4-((5-fluoro-4-(3-(3-oxomorpholino)phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide502N-((1r,4r)-4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2-yl)amino)cyclohexyl)-1′-(4-((2,6-dioxopiperidin-3-yl)-amino)-2-fluorophenyl)-3′-fluoro-[1,4′-bipiperidine]-4-carboxamide503trans-4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2-yl)amino)-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)cyclohexane-1-carboxamide504trans-N-(4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2-yl)amino)cyclohexyl)-1′-(4-((2,6-dioxopiperidin-3-yl)-amino)-2-fluorophenyl)-[1,4′-bipiperidine]-4-carboxamide505trans-2-((1r,4R)-4-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperazin-1-yl)cyclohexyl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide506rac-1-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperazin-1-yl)ethyl)-N-((1r,4r)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)piperidine-4-carboxamide507trans-2-((1r,4R)-4-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperidin-1-yl)cyclohexyl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide508rac-(1r,4R)-N-((1R,4R)-4-(4-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(3-oxomorpholino)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide509trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-((S)-3-hydroxypyrrolidine-1-carbonyl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide510trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-((S)-3-hydroxypyrrolidine-1-carbonyl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide511trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)-N-(trans-4-((5-fluoro-4-(3-((S)-3-hydroxypyrrolidine-1-carbonyl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide512trans-4-(4-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-5-fluoro-1-methyl-1H-indazol-6-yl)piperidin-1-yl)-N-(trans-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide513trans-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-(piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione514trans-3-((3-fluoro-4-(1-((1-(4-((5-fluoro-4-(3-(piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione515trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide516trans-1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-N-(4-((5-fluoro-4-(3-(piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide517trans-4-(4-(4-(((S)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-((trans)-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide518trans-3-((4-(1-((1-(4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-hydroxy-piperidin-4-yl)methyl)piperidin-4-yl)-3-fluorophenyl)amino)piperidine-2,6-dione519(trans)-N-((trans)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(6-(2-oxo-1,3-oxazinan-3-yl)pyridin-2-yl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide520trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(2-oxo-2H-[1,2′-bipyridin]-6′-yl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide521trans-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(2-oxo-piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide522trans-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide5231′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′-fluoro-N-((1r,4r)-4-((5-fluoro-4-(3-(piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide5241′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′-fluoro-N-((1r,4r)-4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)-phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide5251′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′-fluoro-N-((1r,4r)-4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide5261′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-3′-fluoro-N-((1r,4r)-4-((5-fluoro-4-(3-(3-oxomorpholino)phen-yl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide527trans-(1r,4R)-N-((1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide528trans-3-((3-fluoro-4-(4-((4-fluoro-1-(4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclo-hexane-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione529trans-3-((4-(4-((1-((1r,4r)-4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)-4-fluoro-piperidin-4-yl)methyl)piperazin-1-yl)-3-fluorophenyl)amino)piperidine-2,6-dione530trans-3-((3-fluoro-4-(4-((4-fluoro-1-(4-((5-fluoro-4-(3-(3-oxomorpholino)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione531trans-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide532trans-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-[1,4′-bipiperidin]-4-yl)-4-((5-fluoro-4-(3-(3-oxo-morpholino)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide533trans-4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2-yl)amino)-N-(1′-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluoro-phenyl)-[1,4′-bipiperidin]-4-yl)cyclohexane-1-carboxamide5341-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperidin-1-yl)ethyl)-N-((1r,4r)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)piperidine-4-carboxamide535trans-(1r,4R)-4-((4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1H-indazol-6-yl)piperidin-1-yl)methyl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide536trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-(trans-4-((5-fluoro-4-(3-(3-oxo-morpholino)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide537trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-(trans-4-((5-fluoro-4-(3-((S)-3-hydroxy-pyrrolidine-1-carbonyl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide538trans-(1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(6-(3-oxomorpholino)pyridin-2-yl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide539trans-(1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(6-(2-oxo-1,3-oxazinan-3-yl)pyridin-2-yl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide540trans-1-((1-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-4-yl)methyl)-N-((1r,4r)-4-((5-fluoro-4-(3-(2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)piperidine-4-carboxamide541trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-(trans-4-((5-fluoro-4-(3-(piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide5421′-(4-(((S)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-N-((trans)-4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)-phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide5431′-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)-N-((trans)-4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)-phenyl)pyrimidin-2-yl)amino)cyclohexyl)-[1,4′-bipiperidine]-4-carboxamide544trans-4-(4-(4-(((R)-2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)-N-((trans)-4-((5-fluoro-4-(3-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide545trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(6-(3-oxomorpholino)pyridin-2-yl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide546trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(6-(2-oxopiperidin-1-yl)pyridin-2 --- )pyrimidin-2-yl)amino)cyclohexane-1-carboxamide547trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(3-oxomorpholino)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide548trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(2-(1-hydroxycyclobutyl)pyridin-4-yl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide549trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(2-(2-oxopiperidin-1-yl)pyridin-4-yl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide550trans-N-((trans)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(2-(2-oxo-1,3-oxazinan-3-yl)pyridin-4-yl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide551trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(5-methyl-2-oxopyridin-1(2H)-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide552trans-3-((3-fluoro-4-(1-((1-(4-((5-fluoro-4-(3-(3-oxomorpholino)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)piperidine-2,6-dione553trans-3-((3-fluoro-4-(4-((1-(4-((5-fluoro-4-(3-(3-oxomorpholino)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)piperidine-2,6-dione554trans-3-((4-(1-((1-(4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2-yl)amino)cyclohexane-1-carbonyl)piperidin-4-yl)-methyl)piperidin-4-yl)-3-fluorophenyl)amino)piperidine-2,6-dione555trans-3-[4-[4-[[1-[4-[4-(3-cyclopropylphenyl)-5-fluoro-pyrimidin-2-yl]amino]cyclohexanecarbonyl]-4-piperidyl]methyl]piperazin-1-yl]-3-fluoro-anilino]piperidine-2,6-dione556trans-(1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(3-(piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide557trans-(1r,4R)-4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2-yl)amino)-N-((1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)cyclohexane-1-carboxamide558trans-(1r,4R)-N-((1r,4R)-4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2-yl)amino)cyclohexyl)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexane-1-carboxamide559trans-N-(trans-4-((4-(3-cyclopropylphenyl)-5-fluoropyrimidin-2-yl)amino)cyclohexyl)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexane-1-carboxamide560trans-2-((1r,4R)-4-((4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)methyl)cyclohexyl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide561trans-2-((1r,4R)-4-((4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)methyl)cyclohexyl)-N-((1r,4R)-4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide562trans-2-((1r,4R)-4-((4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)methyl)cyclohexyl)-N-((1r,4R)-4-((5-fluoro-4-(3-(3-oxomorpholino)phenyl)pyrimidin-2-yl)amino)cyclohexyl)acetamide563trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxo-1,3-oxazinan-3-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide564(1r,4R)-N-((1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperazin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide565trans-N-(trans-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)cyclohexyl)-4-((5-fluoro-4-(3-(2-oxopiperidin-1-yl)phenyl)pyrimidin-2-yl)amino)cyclohexane-1-carboxamide566trans-(1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(6-(2-oxopiperidin-1-yl)pyridin-2-yl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide567trans-(1r,4R)-4-(4-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)piperidin-1-yl)-N-((1r,4R)-4-((5-fluoro-4-(2-oxo-2H-[1,2′-bipyridin]-6′-yl)pyrimidin-2-yl)amino)cyclohexyl)cyclohexane-1-carboxamide568trans-(1r,4R)-4-(4-(...
Claims
1. A compound of Formula (I′)or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:R is halo;Ring 4 is optional, and when present is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, phenyl optionally substituted with one or more R4b, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b;Ring 3 is a monocyclic ring selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a; 4- to 6-membered heterocyclyl optionally substituted with one or more R3a; phenyl optionally substituted with one or more R3b; or 5- to 6-membered heteroaryl optionally substituted with one or more R3b;Ring 1 is a 4- to 8-membered cycloalkyl or saturated 4- to 8-membered heterocyclyl, each of which is optionally substituted with one or more R1;V is a bond, —C1-4alkylene-, —C(O)—, —C(O)O-#, —OC(O)#-C1-4alkylene-C(O)-#, —C(O)N(RV)-#, —N(RV)C(O)-#, —OC(O)N(RV)-#, —N(RV)—C(O)O#, —C1-4alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; andQ is RQ, or Ring 5,wherein Ring 5 is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R5a, 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and 5- to 12-membered heteroaryl optionally substituted with one or more R5b;orQ is of Formula (i)wherein:Ring A is selected from the group consisting of each of which is optionally substituted with one or more C1-4alkyl or halo;X is a bond, —O—, —NH—, or —NHC(O)—;Ring B is selected from the group consisting of each of which is optionally substituted with one or more halo, C1-4alkyl, C1-4haloalkyl, or OH, and wherein RD is H or C1-4alkyl, wherein # indicates attachment to X;W is a bond, —O—, —NH—, or —NHC(O)—;Ring C is optional, and when present is 4- to 12-membered heterocyclyl optionally substituted with one or more RC;Linker is a bond, —O—, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)—C1-10alkylene, C1-6alkylene-C(O)N(Ry)—C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**, wherein* indicates the point of attachment to Ring C when Ring C is present, and * indicates the point of attachment to W when Ring C is absent; and** indicates the point of attachment to U when Ring 2 is present, and ** indicates the point of attachment to V when Ring 2 is absent;L1 is a bond or C1-6 alkylene;L2 is a 3- to 10-membered cycloalkyl or 4- to 12-membered heterocyclyl optionally substituted with one or more RL; andL3 is C1-10 alkylene, C1-10 alkylene-N(Ry), C(O)—C1-10alkylene, C(O)—C1-10alkylene-N(Ry), C(O)N(Ry)—C1-10alkylene, or C(O)N(Ry)—C1-10alkylene-N(Ry);U is absent when Ring 2 is absent, and is a bond or C(O) when Ring 2 is present;Ring 2 is optional, and when present is selected from the group consisting of 3- to 10-membered cycloalkyl optionally substituted with one or more R2a, 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, 6- to 12-membered aryl optionally substituted with one or more R2b, and 5- to 12-membered heteroaryl optionally substituted with one or more R2b;each R1 is independently oxo, halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, SO2Rx, SO2N(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl;each R2a, R3a, R4a, and R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo;each R2b, R3b, R4b, and R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)Rw, C1-4hydroxyalkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx;each RC is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;each RL is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;each RQ is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;each RV is independently H, halo, OH, C1-4alkyl, or C1-4haloalkyl;each Rw is independently 3- to 10-membered cycloalkyl, phenyl optionally substituted with halo, or 4- to 12-membered heterocyclyl optionally substituted with hydroxyl, C1-4hydroxyalkyl, or C1-4aminoalkyl;each Rx is independently C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl;each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, 3- to 10-membered cycloalkyl, or C1-4alkylene-S(O)n—C1-4alkyl; andeach n is independently 0, 1, or 2;wherein:(a) Ring 1 comprises an intraannular amide, or(b) V comprises an amide or carbamate, or(c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide or carbamate;and wherein:when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl; andwhen Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, Q is RQ, and V is —OC(O)#, then RQ is not tert-butyl.
2. The compound of claim 1, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:V is a bond, —C1-4alkylene-, —C(O)—, —C1-4alkylene-C(O)-#, —C(O)N(RV)-#, —N(RV)C(O)-#, —C1-4 alkylene-C(O)N(RV)-# or —C1-4alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1;Linker is a bond, C1-10alkylene, C1-10alkylene-N(Ry), C(O)C1-10alkylene, C(O)C1-10alkylene-N(Ry), C(O)N(Ry)C1-10alkylene, C(O)N(Ry)C1-10alkylene-N(Ry), C1-6alkylene-C(O)C1-10alkylene, C1-6alkylene-C(O)C1-10alkylene-N(Ry), C1-6alkylene-C(O)N(Ry)—C1-10alkylene, C1-6alkylene-C(O)N(Ry)—C1-10alkylene-N(Ry), or is of the formula *-L1-L2-L3-**,each R2a, R3a, R4a, and R5a is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, C1-4alkylene-S(O)nRx, or oxo;each R2b, R3b, R4b, and R5b is independently halo, C1-4alkyl, C1-4haloalkyl, OH, C1-4alkoxy, C1-4haloalkoxy, C(O)C1-4alkyl, C(O)N(Ry)(Rz), CN, N(Ry)C(O)C1-4alkyl, N(Ry)C(O)C1-4haloalkyl, S(O)nRx, S(O)nN(Ry)(Rz), C1-4alkylene-O—C1-4alkyl, C1-4alkylene-N(Ry)—C1-4alkyl, or C1-4alkylene-S(O)nRx;each RV is independently halo, OH, C1-4alkyl, or C1-4haloalkyl;each Ry and Rz is independently H, C1-4alkyl, C1-4haloalkyl, C1-4alkylene-O—C1-4alkyl, C1-4alkylene-NH—C1-4alkyl, C1-4alkylene-N(C1-4alkyl)-C1-4alkyl, or C1-4alkylene-S(O)n—C1-4alkyl; andeach n is independently 0, 1, or 2;wherein:(a) Ring 1 comprises an intraannular amide, or(b) V comprises an amide, or(c) V is taken together with an atom of Ring 1, Ring 2, or Ring 5 to which it is attached, to form an amide;and wherein:when Ring 3 is 5-membered heteroaryl, Ring 4 is present and is not cycloalkyl or tetrahydropyranyl; andwhen Ring 1 is 8-membered heterocyclyl, Ring 3 is phenyl substituted with CN, Ring 4 is absent, Q is RQ, and V is —OC(O)#, then RQ is not tert-butyl.
3. The compound of claim 1 or 2, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:Ring 1 is a 4- to 8-membered cycloalkyl, saturated 4- to 8-membered heterocyclyl comprising at least one annular ether, saturated 4- to 8-membered heterocyclyl comprising at least one annular amine, or saturated 4- to 8-membered heterocyclyl comprising an annular amide, each of which is optionally substituted with one or more R1;and wherein:(i) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amine, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is —C(O)— or —C1-4alkylene-C(O)-#, wherein # indicates the point of attachment to Ring 1;(ii) when Ring 1 is a 4- to 8-membered heterocyclyl ring comprising at least one annular amide, optionally substituted with one or more R1, then V is attached to an annular nitrogen atom of Ring 1 and is a bond or —C1-4alkylene-; and(iii) when Ring 1 is C4-8 cycloalkyl or a 4- to 8-membered heterocyclyl ring comprising at least one annular ether and no annular amine or annular amide, each of which is optionally substituted with one or more R1, then:(a) V is —C(O)N(RV)-#, —N(RV)C(O)-#, —C1-4alkylene-C(O)N(RV)-# or —C1-4 alkylene-N(RV)C(O)-#, wherein # indicates the point of attachment to Ring 1; or(b) Ring 5 is 4- to 12-membered heterocyclyl optionally substituted with one or more R5a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 5; or(c) Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a, and V is —C(O)— and is attached to an annular nitrogen atom of Ring 2.
4. The compound of any of claims 1-3, wherein R is chloro.
5. The compound of any of claims 1-3, wherein R is fluoro.
6. The compound of any of claims 1-5, wherein Ring 3 is 4- to 6-membered heterocyclyl optionally substituted with one or more R3a.
7. The compound of claim 6, wherein Ring 3 iseach of which is optionally substituted with one or more R3a.
8. The compound of any of claims 1-5, wherein Ring 3 is phenyl optionally substituted with one or more R3b.
9. The compound of any of claims 1-5, wherein Ring 3 is 5- to 6-membered heteroaryl optionally substituted with one or more R3b 10. The compound of claim 9, wherein Ring 3 iseach of which is optionally substituted with one or more R3b.
11. The compound of any of claims 1-8, wherein Ring 4 is absent.
12. The compound of any of claims 1-8, wherein Ring 4 is 3- to 6-membered cycloalkyl.
13. The compound of claim 12, wherein Ring 4 is cyclobutyl, cyclopentyl, or cyclohexyl, optionally substituted with one or more R4a.
14. The compound of any of claims 1-10, wherein Ring 4 is 4- to 6-membered heterocyclyl optionally substituted with one or more R4a.
15. The compound of claim 14, wherein Ring 4 iseach of which is optionally substituted with one or more R4a.
16. The compound of any of claims 1-10, wherein Ring 4 is phenyl optionally substituted with one or more R4b.
17. The compound of any of claims 1-10, wherein Ring 4 is 5- to 6-membered heteroaryl optionally substituted with one or more R4b.
18. The compound of claim 17, wherein Ring 4 isoptionally substituted with one or more R4b.
19. The compound of any of claims 1-5, wherein Ring 3 is phenyl optionally substituted by R3b, and Ring 4 is phenyl optionally substituted by R4b.
20. The compound of any of claims 1-5, wherein Ring 3 is phenyl optionally substituted by R3b, or Ring 4 is phenyl optionally substituted by R4b.
21. The compound of any of claims 1-5, whereinRing 3 is selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R3a, 4- to 6-membered heterocyclyl optionally substituted with one or more R3a, and 5- to 6-membered heteroaryl optionally substituted with one or more R3b; andRing 4 is selected from the group consisting of 3- to 6-membered cycloalkyl optionally substituted with one or more R4a, 4- to 6-membered heterocyclyl optionally substituted with one or more R4a, and 5- to 6-membered heteroaryl optionally substituted with one or more R4b.
22. The compound of any of claims 1-10 or 14-21, wherein Ring 1 iseach of which is optionally substituted with one or more R1, wherein # indicates attachment to V.
23. The compound of claim 22, whereinRing 1 is each of which is optionally substituted with one or more R1; andV is —C(O)N(RV)—, —N(RV)C(O)—, —C1-4alkylene-C(O)N(RV)-#, or —C1-4alkylene-N(RV)C(O)-#, wherein ## indicates the point of attachment to Ring 1.
24. The compound of claim 22, whereinRing 1 is each of which is optionally substituted with one or more R1, wherein # indicates attachment to V; andV is —C(O)— or —C1-4alkylene-C(O)-#, wherein # indicates attachment to Ring 1.
25. The compound of claim 22, whereinRing 1 is each of which is optionally substituted with one or more R1, wherein # indicates attachment to V; andV is bond or —C1-4alkylene-.
26. The compound of any of claims 1-10 or 14-25, wherein Q is RQ.
27. The compound of claim 26, wherein RQ is H, methyl, or acetyl.
28. The compound of any of claims 1-10 or 14-25, wherein Q is Ring 5 and the compound is of Formula (II):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
29. The compound of any of claims 1-10 or 14-25, wherein Q is of Formula (i) and the compound is of Formula (IV):or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
30. The compound of claim 29, wherein Ring A isoptionally substituted with C1-4alkyl or halo.
31. The compound of claim 29 or 30, wherein X is a bond or —NH—.
32. The compound of any of claims 29-31, wherein Ring B iseach of which is optionally substituted with one or more halo or OH, wherein RD is H or C1-4alkyl.
33. The compound of any of claims 29-32, wherein W is a bond or —O—.
34. The compound of any of claims 29-33, wherein Ring C is absent.
35. The compound of any of claims 29-33, wherein Ring C iseach of which is optionally substituted with one or more RC.
36. The compound of any of claims 29-35, wherein Linker is a bond, C1-10alkylene, or C(O)C1-10alkylene.
37. The compound of any of claims 29-36, wherein Ring 2 is present and U is a bond.
38. The compound of any of claims 29-37, wherein Ring 2 is 4- to 12-membered heterocyclyl optionally substituted with one or more R2a.
39. The compound of any of claims 1-23 or 26-38, wherein RV is H.
40. The compound of any of claims 29-37 or 39, wherein Ring 2 is 3- to 10-membered cycloalkyl optionally substituted with one or more R2a.
41. The compound of any of claims 29-39, wherein Ring 2 isor each of which is optionally substituted with one or more R2a, wherein # indicates attachment to V.
42. The compound of any of claims 29-39 or 41, wherein Ring 2 iseach of which is optionally substituted with one or more R2a, wherein # indicates attachment to V.
43. The compound of claim 42, wherein Ring 2 is44. The compound of claim 43, wherein V is —C(O)— and Ring 1 is piperidinyl.
45. The compound of claim 41 or 42, wherein Ring 2 iseach of which is optionally substituted with one or more R2a, wherein # indicates attachment to V.
46. The compound of claim 45, wherein V is —C(O)— and Ring 1 is cyclohexyl.
47. The compound of claim 45, wherein V is —C1-4alkyl-C(O)— and Ring 1 is piperidinyl.
48. The compound of any of claims 27-35, wherein Ring 2, V, and Ring 1 are taken together to form:
49. The compound of claim 48, wherein Ring 2, V, and Ring 1 are taken together to form:
50. The compound of claim 40, wherein Ring 2 is cyclohexyl optionally substituted with one or more R2a.
51. The compound of claim 50, wherein Ring 2 isoptionally substituted with one or more R2a.
52. The compound of claim 50 or 51, wherein V is —C(O)N(RV)-#, wherein # indicates the point of attachment to Ring 1, and wherein Ring 1 is cyclohexyl.
53. The compound of any of claims 50-52, wherein Ring 2, V, and Ring 1 are taken together to form:
54. The compound of claim 1, wherein the compound is selected from the compounds provided in Table 1 and Table 2, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
55. The compound of claim 54, wherein the compound is selected from the compounds provided in Table 1, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
56. The compound of claim 54, wherein the compound is selected from the compounds provided in Table 2, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
57. A pharmaceutical composition, comprising a compound of any of claims 1-56, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable excipient.
58. The pharmaceutical composition of claim 57, wherein the compound is a compound of any of claims 26-28 or 55, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable excipient.
59. The pharmaceutical composition of claim 57, wherein the compound is a compound of any of claims 29-53 or 56, a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable excipient.
60. A method of treating a disease or disorder associated with PIP4K2C, comprising administering to a subject a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57.
61. A method of treating a disease or disorder by modulating the level or activity of PIP4K2C, comprising administering to a subject a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57.
62. The method of claim 61, wherein the method modulates the activity of PIP4K2C, and wherein the method comprises administering to the subject a compound of any of claims 26-28 or 55, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 58.
63. The method of claim 61, wherein the method modulates the level of PIP4K2C, and wherein the method comprises administering to the subject a compound of any of claims 29-53 or 56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 59.
64. The method of any one of claims 60-63, wherein the disease or disorder is a cancer, immune deficiency, autoimmune disease, infectious disease, or a combination thereof.
65. The method of claim 64, wherein the cancer is brain cancer, bladder cancer, breast cancer, triple negative breast cancer, cervical cancer, colorectal carcinoma, colorectal carcinoma with MSI, colorectal carcinoma with MSS, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, leukemia, lung cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, melanoma, Merkel cell carcinoma, multiple myeloma, pancreatic ductal carcinoma, or renal cell carcinoma.
66. The method of claim 65, wherein the cancer is brain cancer, breast cancer, triple negative breast cancer, colorectal carcinoma, colorectal carcinoma with MSI, colorectal carcinoma with MSS, or non-small cell lung cancer.
67. The method of any of claims 60-63, wherein the disease or disorder is a neurodegenerative disease.
68. A method of treating a viral infection by modulating the level of PIP4K2C, comprising administering to a subject a compound of any of claims 29-53 or 56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 59.
69. A method of treating necrotizing soft tissue infection (NSTI), comprising administering to a subject a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57.
70. A method of modulating the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C, comprising administering to a subject a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57.
71. A compound of any of claims 1-56, or the pharmaceutical composition of claim 57, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for use in treating a disease or disorder associated with PIP4K2C in a subject in need thereof.
72. A compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57, for use in treating a disease or disorder by modulating the level or activity of PIP4K2C in a subject in need thereof.
73. The compound for use of claim 72, wherein the compound for use modulates the activity of PIP4K2C, and wherein the compound for use is a compound of any of claims 26-28 or 55, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 58.
74. The compound for use of claim 72, wherein the compound for use modulates the level of PIP4K2C, and wherein the compound for use is a compound of any of claims 29-53 or 56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 59.
75. The compound for use of any one of claims 71-74, wherein the disease or disorder is a cancer, immune deficiency, autoimmune disease, infectious disease, or a combination thereof.
76. The compound for use of claim 75, wherein the cancer is brain cancer, bladder cancer, breast cancer, triple negative breast cancer, cervical cancer, colorectal carcinoma, colorectal carcinoma with MSI, colorectal carcinoma with MSS, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, leukemia, lung cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, melanoma, Merkel cell carcinoma, multiple myeloma, pancreatic ductal carcinoma, or renal cell carcinoma.
77. The compound for use of claim 76, wherein the cancer is brain cancer, breast cancer, triple negative breast cancer, colorectal carcinoma, colorectal carcinoma with MSI, colorectal carcinoma with MSS, or non-small cell lung cancer.
78. The compound for use of any of claims 71-74, wherein the disease or disorder is a neurodegenerative disease.
79. A compound of any of claims 29-53 or 56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 59, for use in treating a viral infection by modulating the level of PIP4K2C in a subject in need thereof.
80. A compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57, for use in treating necrotizing soft tissue infection (NSTI) in a subject in need thereof.
81. A compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57, for use in modulating the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C in a subject in need thereof.
82. Use of a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for the manufacture of a medicament for treating a disease or disorder associated with PIP4K2C in a subject in need thereof.
83. Use of a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for the manufacture of a medicament for treating a disease or disorder by modulating the level or activity of PIP4K2C in a subject in need thereof.
84. The use of claim 83, wherein the use modulates the activity of PIP4K2C, and wherein the compound is a compound of any of claims 26-28 or 55, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
85. The use of claim 83, wherein the use modulates the level of PIP4K2C, and wherein the compound is a compound of any of claims 29-53 or 56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
86. The use of any one of claims 82-85, wherein the disease or disorder is a cancer, immune deficiency, autoimmune disease, infectious disease, or a combination thereof.
87. The use of claim 86, wherein the cancer is brain cancer, bladder cancer, breast cancer, triple negative breast cancer, cervical cancer, colorectal carcinoma, colorectal carcinoma with MSI, colorectal carcinoma with MSS, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, leukemia, lung cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, melanoma, Merkel cell carcinoma, multiple myeloma, pancreatic ductal carcinoma, or renal cell carcinoma.
88. The use of claim 87, wherein the cancer is brain cancer, breast cancer, triple negative breast cancer, colorectal carcinoma, colorectal carcinoma with MSI, colorectal carcinoma with MSS, or non-small cell lung cancer.
89. The use of any of claims 82-85, wherein the disease or disorder is a neurodegenerative disease.
90. Use of a compound of any of claims 29-53 or 56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for the manufacture of a medicament for treating a viral infection by modulating the level of PIP4K2C in a subject in need thereof.
91. Use of a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for the manufacture of a medicament for treating necrotizing soft tissue infection (NSTI) in a subject in need thereof.
92. Use of a compound of any of claims 1-56, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, for the manufacture of a medicament for modulating the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C in a subject in need thereof.
93. A kit, comprising (i) a compound of any of claims 1-56, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or the pharmaceutical composition of claim 57, and (ii) instructions for use in treating an PIP4K-mediated disease, disorder, or condition in an individual in need thereof.
94. The method of claim 65 or 66, wherein the cancer is brain cancer.
95. The method of any of claims 65, 66, or 94 wherein the brain cancer is glioma or glioblastoma.
96. The method of any of claims 65, 66, or 94, wherein the brain cancer is brain stem glioma, gestational trophoblastic tumor glioma, cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, or visual pathway or hypothalamic glioma.
97. The method of claim 65 or 66, wherein the cancer is colorectal cancer.
98. The method of any of claims 65, 66, or 97, wherein the colorectal cancer is colorectal carcinoma, colorectal carcinoma with MSI, or colorectal carcinoma with MSS.
99. The method of any of claims 65, 66, or 97, wherein the colorectal cancer is associated with a hereditary syndrome.
100. The method of claim 65 or 66, wherein the cancer is non-small cell lung cancer.
101. The compound for use of claim 76 or 77, wherein the cancer is brain cancer.
102. The compound for use of any of claims 76, 77, or 101, wherein the brain cancer is glioma or glioblastoma.
103. The compound for use of any of claims 76, 77, or 101, wherein the brain cancer is brain stem glioma, gestational trophoblastic tumor glioma, cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, or visual pathway or hypothalamic glioma.
104. The compound for use of claim 76 or 77, wherein the cancer is colorectal cancer.
105. The compound for use of any of claims 76, 77, or 104, wherein the colorectal cancer is colorectal carcinoma, colorectal carcinoma with MSI, or colorectal carcinoma with MSS.
106. The compound for use of any of claims 76, 77, or 104, wherein the colorectal cancer is associated with a hereditary syndrome.
107. The compound for use of claim 76 or 77, wherein the cancer is non-small cell lung cancer.
108. The use of claim 87 or 88, wherein the cancer is brain cancer.
109. The use of any of claims 87, 88, or 108, wherein the brain cancer is glioma or glioblastoma.
110. The use of any of claims 87, 88, or 108, wherein the brain cancer is brain stem glioma, gestational trophoblastic tumor glioma, cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, or visual pathway or hypothalamic glioma.
111. The use of claim 87 or 88, wherein the cancer is colorectal cancer.
112. The use of claim 87, 88, or 111, wherein the colorectal cancer is colorectal carcinoma, colorectal carcinoma with MSI, or colorectal carcinoma with MSS.
113. The use of claim 87, 88, or 111, wherein the colorectal cancer is associated with a hereditary syndrome.
114. The use of claim 87 or 88, wherein the cancer is non-small cell lung cancer.
115. The method of any one of claims 60-63, wherein the disease or disorder is related to loss-of-function mutations of the phosphoinositide phosphatase FIG. 4.
116. The method of claim 115, wherein the disease or disorder is Charcot-Marie-Tooth.
117. The method of claim 115 or 116, wherein the disease or disorder is Charcot-Marie-Tooth Type 4J.
118. The compound for use of any one of claims 71-74, wherein the disease or disorder is related to loss-of-function mutations of the phosphoinositide phosphatase FIG. 4.
119. The compound for use of claim 118, wherein the disease or disorder is Charcot-Marie-Tooth.
120. The compound for use of claim 118 or 119, wherein the disease or disorder is Charcot-Marie-Tooth Type 4J.
121. The use of any one of claims 82-85, wherein the disease or disorder is related to loss-of-function mutations of the phosphoinositide phosphatase FIG. 4.
122. The use of claim 121, wherein the disease or disorder is Charcot-Marie-Tooth.
123. The use of claim 121 or 122, wherein the disease or disorder is Charcot-Marie-Tooth Type 4J.
124. The method of claim 68, wherein the compound, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is administered in combination with a vaccine for viral infections to enhance the immune response.
125. The compound for use of claim 79, wherein the compound, or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is administered in combination with a vaccine for viral infections to enhance the immune response.
126. The use of claim 90, wherein the medicament is administered in combination with a vaccine for viral infections to enhance the immune response.
